

Vaccines and Global Health: The Week in Review 11 October 2025 :: Issue 817 Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to <u>david.r.curry@centerforvaccineethicsandpolicy.org</u>.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click <u>here</u> to donate and thank you in advance for your contribution.

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: U.S. Immunization and Public Health Governance/Policy/Funding
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers
- :: Think Tanks
- :: Public Consultations/Call for Inputs/Call for Papers

Milestones,	Perspectives
:::::::	

Immunization Initiatives

Ghana launches HPV vaccine to protect over 2 million girls and combat cervical cancer

Accra / Geneva, 8 October 2025 – Ghana Health Services, in partnership with Gavi, the Vaccine Alliance (Gavi), the World Health Organization (WHO), and UNICEF, today launched the country's first nationwide human papillomavirus (HPV) vaccination campaign. The five-day campaign, running from 8 to 11 October, aims to reach 2.4 million girls aged 9 to 14 years, both in and out of school, providing life-saving protection against cervical cancer.

The HPV vaccine is being offered free of charge and will be integrated into Ghana's routine immunisation schedule for 9-year-old girls following the campaign, ensuring long-term and equitable protection for future generations. Health workers across the country have been mobilised to deliver the vaccine through schools, community health centres, and mobile outreach teams, reaching even the most remote areas to ensure no girl is left behind....

Nigeria launches historic integrated vaccination campaign targeting 100 million children

Abuja, 6 October 2025 – ...the Federal Ministry of Health of Nigeria supported by partners today launched the country's largest-ever integrated vaccination campaign, aiming to reach about 109 million children aged 9 months to 14 years with vaccines against measles-rubella (MR), human papillomavirus which protects against cervical cancer (HPV), polio, and other routine immunisations.

The campaign is the result of close collaboration between the Federal Ministry of Health, Gavi, UNICEF, WHO, and a wide network of civil society organizations and donors reflecting unprecedented cooperation among stakeholders.

The nationwide campaign represents a once in a generation opportunity to significantly increase immunisation coverage, reduce the number of unvaccinated children and shift Nigeria's trajectory on vaccine uptake.

Gavi is supporting the initiative with an investment of US\$ 103 million, reinforcing its commitment to equitable access and country-led innovation and is also working hand-in-hand with the Government and States to strengthen systems, share expertise, and ensure long-term sustainability.

The initiative builds on years of investment in health systems, including cold chain infrastructure, workforce capacity, and digital tools, now being leveraged to deliver impact at scale.

The campaign features replicable approaches such as incorporation of data and technology to inform decision-making, track progress, and public engagement. The country-centric approach in design and implementation sets a new benchmark for integrated delivery and offers a model for other countries seeking to scale up immunisation and child health services...

Vaccine	Misinformation

PAHO releases new guides to help combat vaccine misinformation

7 Oct 2025

......

Washington, D.C., October 7, 2025 (PAHO) — The Pan American Health Organization (PAHO) launched six new guides designed to support health workers and other professionals in identifying

and responding to vaccine misinformation—a growing phenomenon that threatens to undermine confidence in immunization and jeopardize public health progress across the Region.

The guides provide **practical tools for key audiences** — including health workers, national immunization program managers, health communicators, journalists, educators, and content creators — to strengthen their capacity to recognize and counter false or misleading messages about vaccines.

"Studies have shown that exposure to vaccine misinformation, even for a short period of time, can negatively influence people's perceptions and their decision to get vaccinated," said Daniel Salas, Executive Manager of the Special Program for Comprehensive Immunization al PAHO. "Even individuals who have been vaccinated in the past can be negatively influenced by misinformation."

The documents outline common strategies used to spread false information, such as using data without scientific evidence, appealing to strong emotions, promoting conspiracy theories, discrediting experts or institutions, and selectively using true information to make false claims appear legitimate.

They also offer guidance on identifying red flags in misleading materials, including frequent spelling or grammatical errors, sensationalist headlines, and the excessive use of capital letters or exclamation marks...

PAHO Guides

- :: A guide for health workers
- :: A guide for EPI managers
- :: Tips for journalists
- :: A guide for educators
- :: Tips for content creators
- :: A guide for risk communication and community engagement teams

:::::::

Clinical Trials

WHO launches the Global Clinical Trials Forum

7 October 2025 Departmental update

WHO has today launched the Global Clinical Trials Forum (GCTF), a global, multi-stakeholder network to strengthen clinical trial environments and infrastructure at national, regional and global levels. The Forum responds to World Health Assembly resolution WHA75.8, which called on WHO to improve the quality and coordination of clinical trials to generate high-quality evidence for health decision-making.

The GCTF supports the implementation of WHO's Guidance for Best Practices for Clinical Trials, which sets out principles and actions to improve the design, conduct, oversight and use of trials. It is further guided by the Global Action Plan for Clinical Trial Ecosystem Strengthening (GAP-CTS), which translates the guidance into nine priority action areas addressing barriers across current clinical trial ecosystems.

By connecting diverse stakeholders including Member States, regulators, ethics authorities, funders, researchers, civil society and patient/community engagement organizations, the GCTF provides a collaborative platform for members to disseminate WHO guidance and best practices, engage and advocate with stakeholders to promote adoption of standards, and share

knowledge to strengthen capacity and advance inclusive, ethical and impactful clinical trials.

Members have the opportunity to engage in thematic working groups to:

:: advance implementation of best practices;

:: improve clinical trial readiness in health systems; and

:: ensure that evidence generation is equitable and sustainable.

Launch members include:

AIDS Vaccine Advocacy Coalition

Catholic Bishops Conference of India (CBCI) Society for Medical Education (St. John's Medical College)

Christian Medical College Vellore

Coalition for Epidemic Preparedness Innovations

Cochrane Collaboration

Egyptian Drug Authority

European Clinical Research Infrastructure Network

European Organization for Research and Treatment of Cancer

Health Research Authority (UK)

Indian Council of Medical Research

Indonesia Clinical Research Center

International Vaccine Institute

Malaysia Institute of Clinical Research

McMaster University

Medicines for Malaria Venture

National Institute for Health and Care Research (UK)

National University of Singapore

Nepal Health Research Council

PATH

Quality by Randomization Limited (Protas)

Singapore Clinical Research Institute

South Africa Medical Research Council

The European Patients' Academy for Therapeutic Innovation

The George Institute for Global Health

The Global Health Network

The International Federation of Pharmaceutical Manufacturers & Associations

University of Oxford

The Global Clinical Trials Forum represents a significant step towards ensuring that all countries have the capacity to generate reliable evidence to guide health policy and practice. **Membership of the Forum is open to eligible stakeholder organizations committed to implementing WHA75.8** and WHO's Guidance for Best Practices for Clinical Trials. Members gain opportunities to collaborate with global experts, contribute to key initiatives, and take part in shaping the future of clinical trial ecosystems.

:::::::

<u>CEPI partners with AVAREF to boost clinical trial application reviews in Africa</u>

BRAZZAVILLE/OSLO, 7 OCT—New funding to the AdVAncIng Clinical TRials Excellence in
Africa (AVAREF) could help accelerate the development of life-saving vaccines to contain
infectious disease outbreaks on the continent.

The Coalition for Epidemic Preparedness Innovations (CEPI) is providing \$1 million to AVAREF as part of a new two-year project to enhance the efficiency with which African regulatory agencies and ethics committees—who are already part of the AVAREF network—review and make emergency decisions on multi-country clinical trial applications. Part of the funding will also support AVAREF to coordinate and further finetune the procedure for issuing scientific advice to developers, an important element which aids the development and eventual licensure of vaccines and other health products.

At present, not all countries on the continent have emergency review and scientific advice procedures suitable for public health emergencies. In certain cases, the standard time to review a clinical trial application, often driven by sequential ethics and regulatory reviews, could take anywhere between 6-18 months - by which point an outbreak could have spread beyond containment.

With CEPI funding, experts at national regulatory authorities and ethics committees across Africa will gain further experience in accelerating the regulatory process by participating in existing AVAREF scientific advice, joint emergency reviews and simulation exercises. The emergency joint review process is used by AVAREF to bring together relevant national authorities of regulators and ethics committees and decide whether a clinical trial—typically submitted to AVAREF by a vaccine developer looking to run a multi-country study—is to be approved and enable recruitment of participants in as little as 10 to 15 days from receiving the application, without compromising robust technical considerations...

Jacqueline Rodgers, Senior Regulatory Affairs Lead for Africa at CEPI, said: "From Mpox to Marburg and Ebola Sudan to Lassa fever, Africa has tackled an abundance of deadly outbreaks in recent years and vaccines are urgently needed to mitigate these persistent threats. **Each day counts in an outbreak, so rapid meaningful response to requests for scientific advice and well-designed vaccine clinical trials that meet the criteria for emergency approval by relevant authorities can be a gamechanger in helping to control the spread of a disease.** Building robust, pandemic-ready regulatory systems on the continent advances Africa's self-sufficiency, with more streamlined and efficient AVAREF processes acting as models that could drive the establishment of similar AVAREF-like forums in Asia and the Americas to fulfil a vision of global preparedness."...

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: U.S. Immunization and Public Health Governance/Policy/Funding
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers
- :: Think Tanks
- :: Public Consultations/Call for Inputs/Call for Papers

::::::::

WHO & Regional Offices [11 Oct 2025]

https://www.who.int/news

Selected News/Announcements/Statements

9 October 2025 Departmental update

WHO announces the development of new recommendations on HTLV-1

8 October 2025 Departmental update

WHO releases new guidelines on tuberculosis and undernutrition

7 October 2025 Departmental update

WHO launches the Global Clinical Trials Forum

6 October 2025 News release

WHO tobacco trends report: 1 in 5 adults still addicted to tobacco

6 October 2025 Departmental update

WHO publishes first-of-its-kind guidance to support government decision-making on public health and social measures

5 October 2025 Joint News Release

Global health agencies issue new recommendations to help end deaths from postpartum haemorrhage

:::::::

WHO Vaccines and Immunization [IVB]

https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1 Updates

No new digest content identified.

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: Uganda strengthens Ebola outbreak preparedness

09 October 2025

:: Fighting HIV in Burkina Faso: From fear to hope

06 October 2025

WHO Region of the Americas PAHO

:: 7 Oct 2025

PAHO releases new guides to help combat vaccine misinformation

Washington, D.C., October 7, 2025 (PAHO) — The Pan American Health Organization (PAHO) launched six new guides designed to support health workers and other professionals in identifying and responding to vaccine misinformation—a growing phenomenon that threatens to undermine confidence in immunization and jeopardize public health progress across...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

No new digest content identified.

WHO Eastern Mediterranean Region EMRO

:: Every door matters: Yemen's fight for a polio-free future

7 October 2025

WHO Western Pacific Region

No new digest content identified.

::::::

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

No new digest content identified.

::::::

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

No new digest content identified.

::::::

Weekly Epidemiological Record

Vol. 100, No. 39, pp. 411–438 26 September 2025

https://www.who.int/publications/journals/weekly-epidemiological-record

:: WHO position paper: Pneumococcal conjugate vaccines in infants and children aged <5 years – September 2025

[Latest edition]

:::::::

New WHO Publications

https://www.who.int/publications Selected

10 October 2025

Mapping climate change and health indicators

Overview

This review sheds light on how countries are measuring the health impacts of climate change. It examines the indicators countries are using in their vulnerability and adaptation (V&A) assessments, as well as in their Health National Adaptation Plans (HNAPs). The review analyzed 31 reports from 22 countries—15 V&As and 16 HNAPs—spanning all WHO regions. These documents, published by members of the Alliance for Transformative Action on Climate and Health (ATACH), were available on the ATACH website between January 2015 and November 2024.

The review found wide variation in how countries track climate-related health risks, though common patterns also emerged. Indicators were grouped into key areas linking climate change to health: hazards, exposures, vulnerabilities, health outcomes, impacts on health systems, future climate and

health risks, and enabling factors such as policies and resources. In total, 3,880 indicators were recorded. After eliminating overlaps and merging similar ones, the researchers identified 1,684 unique indicators.

10 October 2025

Elimination of human onchocerciasis: progress report, 2024–2025

10 October 2025

<u>Progress in eliminating onchocerciasis in the WHO Region of the Americas: Report from the Inter-American...</u>

10 October 2025

Access to medical products in the South-East Asia Region 2025

7 October 2025

WHO consolidated guidelines on tuberculosis: module 6: tuberculosis and comorbidities, 2nd ed.

6 October 2025

<u>Eleventh Meeting of South-East Asia Region Polio Network and Capacity Building Workshop on Risk Assessment...</u>

......

Africa

Africa CDC [11 Oct 2025]

https://africacdc.org/

Press Releases, Statements [Selected]

Africa CDC Launches the African Manufacturing Market Intelligence & Network Analysis (AMMINA) Platform

10 October 2025

New data-driven platform strengthens health manufacturing, investment and regional collaboration across the continent.

Press Releases

Africa CDC and Government of South Africa Announce 4th International Conference on Public Health in Africa (CPHIA), 22–25 October 2025, Durban
7 October 2025

<u>Launch: Joint Coordination Team (JCT) to Strengthen Africa's Health Architecture</u> September 24, 2025

The African Union Commission (AUC), through its Department of Health, Humanitarian Affairs and Social Development (HHS), in collaboration with the World Health Organization, Regional Office for Africa (WHO-AFRO), Africa Centres for Disease Control and Prevention (CDC), African Union Development Agency (AUDA-NEPAD), the African Medicines Agency (AMA), WHO- (Eastern Mediterranean Regional Office (EMRO), and the Regional Economic Communities (RECs), successfully launched on September 24, 2025, the Joint Coordination Team (JCT) on the margins of the 80th Session of the United Nations General Assembly (UNGA 80) in New York.

::::::

China - CDC+

http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China [11 Oct 2025]

http://en.nhc.gov.cn/

News

No new digest content identified.

National Medical Products Administration – PRC [11 Oct 2025]

http://english.nmpa.gov.cn/

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (7)

2025-10-10 / No. 41

PDF of this issue

- <u>Perspectives: Artificial Intelligence in Health and Medicine: Progress, Challenges, and</u> Recommendations
- <u>Preplanned Studies: Evaluating Large Language Models' Potential in Field Epidemiology</u> <u>Investigation Based on Chinese Context— Zhejiang Province, China, 2025</u>
- Outbreak Reports: The Cluster of Mpox (Clade Ib) Infections Yiwu City, Zhejiang Province, China,
 July—August 2025

::::::

Europe

European Centre for Disease Prevention and Control

https://www.ecdc.europa.eu/en

News/Updates/Reports/Publications [Selected]

Surveillance and monitoring

Communicable disease threats report, 4 -11 October 2025, week 41

10 Oct 2025

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 4 -11 October 2025 and includes updates on respiratory virus epidemiology in the EU/EEA, chikungunya, West Nile virus, dengue, Crimean-Congo haemorrhagic fever, Ebola, measles, and Middle East respiratory syndrome (MERS-CoV).

Surveillance and monitoring

Seasonal surveillance of dengue in the EU/EEA

10 Oct 2025

Update providing weekly overview of the countries and areas where dengue cases have been reported.

Surveillance and monitoring

Seasonal surveillance for chikungunya virus disease in the EU/EEA for 2025

10 Oct 2025

Update providing weekly overview of the countries and areas where chikungunya virus disease cases have been reported.

European Medicines Agency [EMA]

https://www.ema.europa.eu/en/news News & Press Releases No new digest content identified.

::::::::

India

National Centre for Disease Control

Directorate General of Health Services, Ministry of Health & Family Welfare Announcements
No new digest content identified.

U.S. Immunization and Public Health Governance/Policy/Funding

Given the continuing extraordinary situation in the U.S., we have established a separate section of the digest to capture and organize key content. Please note that we will selectively include external analysis and comment, indenting this content under the relevant organization/action. We recognize that despite the volume of content in this section, this summary is indicative and not exhaustive.

White House, HHS, FDA, CDC+

White House

<u>Presidential Actions – Executive Orders; Memoranda; Proclamations</u>

<u>AstraZeneca announces historic agreement with US Government to lower the cost of medicines for American patients</u>

10 October 2025

- :: Delivers on all four of President Trump's requests reducing cost of medicines
- :: Preserves America's role as a global powerhouse in biopharmaceuticals innovation
- :: AstraZeneca to invest \$50bn in manufacturing and R&D to support domestic sourcing
- ... At a landmark event at the White House, AstraZeneca CEO Pascal Soriot joined President Trump and members of his Administration to confirm the Company voluntarily met all requests set out in the President's 31 July letter. The Company agrees to a range of measures which will enable American patients to access medicines at prices that are equalized with those available in wealthy countries...

Department of State

Press Releases

No new digest content ide

No new digest content identified.

HHS

Press Room

<u>CDC Immunization Schedule Adopts Individual-Based Decision-Making for COVID-19 and Standalone Vaccination for Chickenpox in Toddlers</u>

October 6, 2025 Press Release [See CDC below]

NIH

http://www.nih.gov/ News Releases No new digest content identified.

Exclusive: After months in limbo, four NIH institute directors fired

Two leaders removed by Trump administration had hoped to stay at agency as in-house investigators

Science, 2 Oct 2025 By Jocelyn Kaiser

Four institute directors at the National Institutes of Health (NIH) and another top agency official who have been in professional limbo since being placed on administrative leave in the spring have now been fired, Science Insider has learned.

They are Jeanne Marrazzo, director of the National Institute of Allergy and Infectious Diseases (NIAID), who in a recently filed federal whistleblower complaint says her removal was for political reasons; Diana Bianchi, director of the National Institute of Child Health and Human Development; Eliseo Pérez-Stable, who directed the National Institute on Minority Health and Health Disparities; Shannon Zenk, director of the National Institute of Nursing Research; and NIH Deputy Director for Program Coordination, Planning, and Strategic Initiatives Tara Schwetz.

All received letters from NIH or the Department of Health and Human Services (HHS), its parent agency, in the past few days informing them that their appointments had expired or were being terminated...

FDA

Press Announcements No new digest content identified.

FDA CBER

Latest News

October 9, 2025 - Approval Letter - INSTI HIV Self Test

FDA VRBPAC [Vaccines and Related Biological Products Advisory Committee]

Advisory Committee Calendar

Vaccines and Related Biological Products Advisory Committee October 9, 2025 Meeting Announcement - 10/09/2025

Event Materials

FDA Pediatric Advisory Committee Meeting

Advisory Committee Calendar

Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public **Docket: Request for Comments**

A Notice by the Food and Drug Administration on 10/02/2025

DATES: The meeting will be held on virtually on **November 13, 2025**, from 10:00 a.m. to 4:00 p.m. Eastern Time (ET). Comments: November 5, 2025

CDC

http://www.cdc.gov/media/index.html Latest News

CDC Immunization Schedule Adopts Individual-Based Decision-Making for COVID-19 and **Standalone Vaccination for Chickenpox in Toddlers**

October 6, 2025

The Centers for Disease Control and Prevention (CDC) today updated its adult and child immunization schedules to apply individual-based decision-making to COVID-19 vaccination and recommend that toddlers receive protection from varicella (chickenpox) as a standalone immunization rather than in combination with measles, mumps, and rubella vaccination.

The immunization schedules adopt recent recommendations by the CDC Advisory Committee on Immunization Practices (ACIP), which were approved last week by Acting Director of the CDC and Deputy Secretary of Health and Human Services Jim O'Neill. The schedules will be updated on CDC.gov by October 7, 2025.

"Informed consent is back," said Deputy Secretary O'Neill. "CDC's 2022 blanket recommendation for perpetual COVID-19 boosters deterred health care providers from talking about the risks and benefits of vaccination for the individual patient or parent. That changes today.

"I commend the doctors and public health experts of ACIP for educating Americans about important vaccine safety signals. I also thank President Trump for his leadership in making sure we protect children from unintended side effects during routine immunization."

Unlike the COVID-19 primary series vaccination pioneered by Operation Warp Speed (OWS) that reached an <u>estimated</u> nearly 85% of the U.S. adult population, just 23% of adults followed the CDC's most recent seasonal booster recommendation according to its <u>National Immunization Survey</u>. The booster shots prompted widespread risk-benefit concerns about their safety and efficacy as the COVID-19 virus became endemic following population-wide immunity acquired during the pandemic and OWS. ACIP's recommendation emphasized that the risk-benefit of vaccination in individuals under age 65 is most favorable for those who are at an increased risk for severe COVID-19 and lowest for individuals who are not at an increased risk, according to the CDC list of COVID-19 risk factors. The U.S. Food and Drug Administration has approved marketing authorization for COVID-19 vaccines for individuals who have one or more of these risk factors, as well as for individuals age 65 and older.

Individual-based decision-making is referred to on the CDC's immunization schedules as vaccination based on shared clinical decision-making, which references providers including physicians, nurses, and pharmacists. It means that the clinical decision to vaccinate should be based on patient characteristics that unlike age are difficult to incorporate in recommendations, including risk factors for the underlying disease as well as the characteristics of the vaccine itself and the best available evidence of who may benefit from vaccination.

Like routine recommendations, individual-based-decision-making allows for immunization coverage through all payment mechanisms including entitlement programs such as the Medicare, Medicaid, Children's Health Insurance Program, and the Vaccines for Children Program, as well as insurance plans regulated by the Affordable Care Act.

The CDC child and adolescent immunization schedule's new recommendation of standalone chickenpox vaccination for toddlers through age three follows evidence <u>presented</u> to ACIP by the CDC Immunization Safety Office's that healthy 12–23 months old toddlers have increased risk of febrile seizure seven to 10 days after vaccination for the combined measles, mumps, rubella, and varicella vaccine compared to those given immunization for chickenpox separately. The combination vaccine doubles the risk of febrile seizures without conferring additional protection from varicella compared to standalone vaccination.

Vaccine Education Center, CHOP June 17, 2025

Shared clinical decision making — what does it mean for vaccines?

by Dorit Rubinstein Reiss 2025-10-08 [Excerpt]

...On October 6, 2025, the Acting Director of CDC, Deputy Secretary Jim O'Neill, signed the recommendation (CDC Director's signature is needed for the recommendation to become final; Vaccines for Children recommendations are different). Director O'Neill added the following statement:

"Informed consent is back," said Deputy Secretary O'Neill. "CDC's 2022 blanket recommendation for perpetual COVID-19 boosters deterred health care providers from talking about the risks and benefits of vaccination for the individual patient or parent. That changes today."

The recommendation and these comments caused substantial confusion, in part because they do not correctly reflect what shared clinical decision making is, and in part because of the confusing language of the committee – "individual decision making" is not a legal term, and does not mean shared clinical decision making. Language matters in law...

So, the bottom line is — shared clinical decision making does not mean "let's have more informed consent." It means "let's not give the vaccines to everyone, only to those who need them," and creates real confusion around how the process should be implemented.

It leads to less vaccine uptake and potentially insurance coverage issues, and most importantly, it's a signal from ACIP that not everyone should get the vaccine, only special cases, which can lead to lower vaccine uptake. I suspect that's part of the revised ACIP's intent, but Director O'Neill should know better than to mischaracterize what this means.

CDC – Immunization Safety Office (ISO)

CDC's Vaccine Safety Monitoring Office Performed Well During COVID-19
Pandemic; Steps Needed to Safeguard Office's Independence, Improve
Communications

National Academies-Sciences-Engineering-Medicine [NASEM] News Release October 7, 2025

WASHINGTON — The Centers for Disease Control and Prevention's Immunization Safety Office (ISO) carried out scientifically robust, timely, and effective monitoring and evaluation of vaccine risks throughout the COVID-19 pandemic, says a new report from the National Academies of Sciences, Engineering, and Medicine. The office's proactive identification of emerging vaccine risk concerns informed critical public health decisions.

The report identifies ongoing challenges related to public trust, transparency, and the perception of ISO's independence, however. The perceived overlap between ISO's risk monitoring activities and CDC's broader efforts to encourage vaccine use continues to raise public concerns about the objectivity of risk assessments.

ISO should clearly distinguish its role from CDC's efforts to encourage vaccination, the report says.

CDC should protect ISO's independence, keeping the office operationally and administratively insulated from units in CDC that carry out promotion or policymaking activities, such as promoting vaccination.

"The COVID pandemic underscored ISO's critical role in vaccine risk monitoring and evaluation," said Jane Henney, chair of the committee that conducted the study. "Moving forward, enhancing transparency and distinguishing ISO's role from broader CDC efforts to encourage vaccination will be essential to address emerging vaccine risk challenges and to maintain public trust."...

The study — undertaken by the <u>Committee to Review the Centers for Disease Control and Prevention's COVID-19 Vaccine Safety Research and Communications</u> — **was sponsored by the Centers for Disease Control and Prevention.** The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide independent, objective analysis and advice to the nation to solve complex problems and inform public policy decisions related to science, engineering, and medicine. They operate under an 1863 congressional charter to the National Academy of Sciences, signed by President Lincoln.

ACIP

Meeting - September 18-19, 2025

- Final ACIP September 18-19, 2025 Meeting Agenda (posted 9-19-2025)
- Anticipated Votes
- ACIP Presentation Slides: September 18-19, 2025 Meeting
- YouTube Live Stream Link 9-18-2025
- YouTube Live Stream Link 9-19-2025
- Written Public Comments

ACIP – Childhood and Adolescent Immunization Schedule Workgroup

Terms of Reference UPDATED: October 8, 2025 [Excerpt]

...In accordance with the ACIP Charter, the Childhood and Adolescent Immunization Schedule WG and its members will prepare information for the ACIP members to enable them to make recommendations that consider:

- The timing and order of different vaccines.
- The concurrent administration of various vaccines.
- The safety of ingredients that are present in multiple different vaccines.
- The efficacy and safety of different vaccine schedules used in different countries.
- Implementation considerations, including burden on healthcare and payor systems, economic impact, and acceptability and feasibility with input from pediatric healthcare providers and parents.

The WG will also consider these issues for particular subgroups of children, such as children born pre-maturely, children with immune deficiencies, or children with cancer. The WG will engage external subject matter experts, as needed, to support implementation of key activities.

TOPICS UNDER DISCUSSION BY THE WORKGROUP

In accordance with the ACIP Charter and in a multi-year effort, the Childhood and Adolescent Immunization Schedule WG members will work with expert consultants as appropriate and in accordance with FACA statutory requirements and policies, to prepare information for the ACIP members to enable them to make recommendations on:

- The timing and order of different vaccines. For example, should the last toddler dose of the non-live DTaP vaccine be given before, on the same day, or after the MMR vaccine?
- The concurrent administration of various vaccines and other immunizing products such as monoclonal antibodies. For example, does the risk of post-vaccination febrile seizures increase or decrease with concomitant administration?

- The safety of ingredients that are present in multiple different vaccines. For example, do either of the two different aluminum adjuvants increase the risk of asthma?
- The efficacy and safety of different vaccine schedules used in different countries.
 For example, are there differences in efficacy or safety between the U.S. and Danish childhood vaccine schedules?...

MMWR Weekly

https://www.cdc.gov/mmwr/index2025.html

September 25, 2025 / No. 36

No new edition identified.

National Vaccine Program Committee (NVAC)

https://www.hhs.gov/vaccines/about/index.html

Upcoming Meetings/Latest Updates

No 2025 meeting dates posted.

Advisory Commission on Childhood Vaccines (ACCV)

https://www.hrsa.gov/advisory-committees/vaccines/meetings

Next ACCV Meeting - TBD [To be re-scheduled from original date January 29, 2025]

:::::::

NSF

News

No new digest content identified.

::::::::

U.S. Congress

House of Representatives

No new digest content identified.

U.S. Senate

Senate Health, Education, Labor, and Pensions (HELP) Committee

No new digest content identified.

:::::::

Supreme Court, Federal & Appellate Courts

No new digest content identified.

::::::::

U.S. States

No new digest content identified.

:::::::



U.S. Medical Societies, Health Organizations

American Academy of Pediatrics (AAP)

https://www.aap.org/en/news-room/news-releases-from-the-aap/

(Accessed 04 Sep 2025)

News

No new digest content identified.

American College of Physicians (ACP)

https://www.acponline.org/more-acp-news

(Accessed 04 Sep 2025)

ACP News

Texas measles outbreak linked to low MMR vaccine rates in schools

10/10/25

Annals of Internal Medicine

Infectious Diseases Society of America (IDSA)

https://www.idsociety.org/

(Accessed 04 Sep 2025)

News

No new digest content identified.

American Public Health Association (APHA)

https://www.apha.org/news-and-media/news-

<u>releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc</u>

(Accessed 04 Sep 2025)

News Releases

APHA announces 2025 awards for excellence in public health

October 10, 2025

Every year, the American Public Health Association honors excellence in public health leadership and innovation, from state and local health officials to those speaking up for public health from the halls of Congress.

Society for Maternal-Fetal Medicine (SMFM)

https://www.smfm.org/

(Accessed 04 Sep 2025)

News

No new digest content identified.

Massachusetts Public Health Alliance (MPHA)

https://mapublichealth.org/press-room/

(Accessed 04 Sep 2025)

Press Room

No new digest content identified.

American Medical Association (AMA)

https://www.ama-assn.org/press-center

(Accessed 04 Sep 2025)

Press Center

No new digest content identified.

American Academy of Family Physicians (AAFP)

https://www.aafp.org/news/media-center.html (Accessed 04 Sep 2025) Statements, Releases No new digest content identified.

American Geriatrics Society (AGS)

https://www.americangeriatrics.org/media-center (Accessed 04 Sep 2025) Recent Press Releases [No new digest content identified]

American Osteopathic Association (AOA)

https://osteopathic.org/news/
(Accessed 04 Sep 2025)

Latest News
[No new digest content identified]

National Medical Association (NMA)

https://nmanet.org/blog/ (Accessed 04 Sep 2025) Latest News [No new digest content identified]

National Foundation for Infectious Diseases (NFID)

https://www.nfid.org/news-updates/ (Accessed 04 Sep 2025) News and Updates [No new digest content identified]

.....

Civil Society – Individuals, Organizations, Institutions

Six surgeons general: It's our duty to warn the nation about RFK Jr.

We took an oath to declare dangers when we found them. We're doing that again today.

By Jerome Adams, Richard Carmona, Joycelyn Elders, Vivek Murthy, Antonia Novello and David Satcher The writers are all former U.S. surgeons general.

Opinion

The Washington Post, October 7, 2025

As former U.S. surgeons general appointed by every Republican and Democratic president since George H.W. Bush, we have collectively spent decades in service as the Nation's Doctor. We took two sacred oaths in our lifetimes: first, as physicians who swore to care for our patients and, second, as public servants who committed to protecting the health of all Americans.

Today, in keeping with those oaths, we are compelled to speak with one voice to say that the actions of Health and Human Services Secretary Robert F. Kennedy Jr. are endangering the health of the nation. Never before have we issued a joint public warning like this. But the profound, immediate and

unprecedented threat that Kennedy's policies and positions pose to the nation's health cannot be ignored.

Despite differences in perspectives, we have always been united in an unwavering commitment to science and evidence-based public health. It is that shared principle that led us to this moment.

Over recent months, we have watched with increasing alarm as the foundations of our nation's public health system have been undermined. Science and expertise have taken a back seat to ideology and misinformation. Morale has plummeted in our health agencies, and talent is fleeing at a time when we face rising threats — from resurgent infectious diseases to worsening chronic illnesses.

Repairing this damage requires a leader who respects scientific integrity and transparency, listens to experts and can restore trust to the federal health apparatus. Instead, Kennedy has become a driving force behind this crisis.

HHS is the <u>one of the largest civilian agencies</u> in the federal government, with <u>a nearly \$2 trillion</u> <u>budget</u> and oversight of programs and agencies that touch every American family and business: Medicare, Medicaid, the Centers for Disease Control and Prevention, the Food and Drug Administration, the National Institutes of Health and more. It requires steady, ethical leadership grounded in science.

By contrast, Kennedy has spent decades advancing dangerous and discredited claims about vaccines — most notoriously, the thoroughly discredited theory that childhood <u>vaccines cause autism</u>. He has promoted <u>misinformation about the HPV vaccine</u>, which protects against cervical cancer, and he has repeatedly misrepresented the risks <u>of mRNA technology</u> and coronavirus vaccines, despite their lifesaving impact during the pandemic.

This year, as the United States faced its worst measles outbreak in more than 30 years, Kennedy deemphasized vaccination and directed agency resources toward unproven vitamin therapies. The result: months-long outbreak, three preventable deaths and the first measles-related child death in the U.S. in over two decades.

More recently, Kennedy removed every member of the <u>Advisory Committee on Immunization Practices</u>, replacing its scientific experts with individuals who often lacked basic qualifications, some of whom are vaccine conspiracy theorists. The new committee has <u>already begun casting doubt</u> on the hepatitis B vaccine for newborns, despite decades of data affirming its effectiveness and strong safety profile. Discrediting vaccines undermines one of the most important public health tools in American history. Thanks to widespread immunization, we eradicated smallpox, eliminated polio in the U.S. and prevented an estimated 1.1 million deaths and 508 million infections among children born between <u>1994 and 2023</u>. Operation Warp Speed, initiated under President Donald Trump, brought lifesaving mRNA vaccines to the world in record time.

Yet Kennedy continues to ignore science and the public's wishes. Most recently, HHS proposed new warning labels on products containing acetaminophen (Tylenol), citing a supposed link between prenatal use and autism. This move has been widely condemned by the scientific and medical communities, who have pointed out that the available research is inconclusive and insufficient to justify such a warning. In an extraordinary and unprecedented response, the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists and other leading health organizations issued public guidance urging physicians and patients to disregard HHS's recommendation. Instead of helping pregnant women make informed decisions during a critical period in their lives, Kennedy's decisions risk causing confusion, fear and harm.

Rather than combating the rapid spread of health misinformation with facts and clarity, Kennedy is amplifying it. The consequences aren't abstract. They are measured in lives lost, disease outbreaks and an erosion of public trust that will take years to rebuild.

It is essential to note that good science and public health require not only evidence but also people — the scientists, public health professionals and civil servants whose expertise protects millions of Americans. Yet under Kennedy's leadership, the HHS workforce has been badly damaged. He has silenced and sidelined hundreds of scientists, public health officials and medical professionals, creating an atmosphere of fear and distrust. Many of the nation's top public health professionals — people we have worked with during crises — have resigned or retired early. They describe a culture of intimidation, where scientific findings are censored, evidence is disregarded and career officials are pressured to rubber stamp conclusions that are not backed by science.

The <u>shooting at CDC headquarters</u> in Atlanta this year only deepened the crisis. As former commanding officers of the U.S. Public Health Service Commissioned Corps, we know that caring for your people is the sacred duty of a leader. Yet, in the face of tragedy, <u>Kennedy denigrated CDC staff</u> as corrupt and repeated conspiracy theories that contribute to the targeting of the very staff he is charged with protecting. We will not soon forget the heartbreaking calls we received from CDC employees, expressing how scared and betrayed they felt for simply doing their jobs to serve the American people.

It's worth reminding ourselves what Kennedy puts at risk. The FDA approves lifesaving drugs and holds pharmaceutical companies to high standards of safety and effectiveness. NIH pursues and funds cutting-edge research. CDC leads in emergencies from pandemics to opioids to natural disasters. Agencies at HHS spearhead efforts to address issues regarding mental health, substance-use disorders, primary care shortages and health insurance coverage for millions of seniors, disabled individuals, and low-income Americans. Mismanaging HHS endangers America's health, undermines national security and damages our economic resilience and international credibility.

America's health systems are essential to the well-being of the nation. We are clear-eyed about the fact that these systems need to be improved, including paying more attention to areas such as disease prevention, mental health and chronic illness. But reform must be grounded in truth, transparency and scientific evidence. Without this foundation, we risk not only halting progress but reversing it — costing lives in the process.

Secretary Kennedy is entitled to his views. But he is not entitled to put people's health at risk. He has rejected science, misled the public and compromised the health of Americans. The nation deserves a health and human services secretary who is committed to scientific integrity and can restore morale and trust in our public health agencies. Having served at senior levels in government, we know that politics are complicated. But this is bigger than politics. It's about putting the health of Americans first.

:::::::


Poll: After President Trump's Warning, Many People Are Uncertain About Whether Tylenol Use in Pregnancy Causes Autism; Most Republicans Say It Is Probably or Definitely True Kaiser Family Foundation/KFF Oct 9, 2025

News Release


Following the Trump administration's warning last month that using acetaminophen – the active ingredient in Tylenol – during pregnancy can increase the risk of autism in children, very few (4%) adults say the claim about a causal relationship is "definitely true," a new KFF Tracking Poll on Health Information and Trust finds.

Many Are Uncertain If Tylenol Use During Pregnancy Increases Risk of Autism in Children, Most Republicans Say it is Probably or Definitely True

Do you think that it is **definitely true**, **probably true**, **probably false**, or **definitely false** that taking Tylenol during pregnancy increases the risk of the child developing autism?



The latest poll shows that the public's trust in the CDC continues to slide and is now at its lowest level since the start of the COVID-19 pandemic. Half of the public now say they have "a great deal" (18%) or "a fair amount" (32%) of trust in the CDC to provide reliable vaccine information, down from 57% in July and 63% in September 2023.



Among partisans, Democrats remain the most likely to say they trust the CDC on vaccines (64%), though that is down 24 percentage points since 2023. Among independents, nearly half (47%) say they trust the CDC on vaccines, down from 61% in 2023, while the share of Republicans who trust the CDC's vaccine information is lower (39%) but similar to where it stood in 2023 (40%).

Compared to the CDC, more people say they trust the American Academy of Pediatrics (69% of parents) and the American Medical Association (64% of all adults) to provide reliable information about vaccines, two groups that have recently been removed from federal vaccine working groups...

::::::::

Vaccine poll asks parents what they think about RFK Jr. and their pediatricians

A Washington Post-KFF poll finds that pediatricians are the most trusted source for vaccine information and that confidence in them is a strong predictor of vaccination. By Lena H. Sun, Rachel Roubein and Scott Clement

The Washington Post, October 10, 2025 *[paywall]*

Parents who distrust their child's pediatrician more likely to skip or delay vaccines and criticize vaccine testing, recommendations

Percentage of each group of parents who skipped or delayed a child's vaccine besides flu/covid, say childhood vaccines do not go through enough safety testing and say the CDC recommends too many vaccines for children.

	U.S. PARENTS OVERALL	TRUST CHILD'S PEDIATRICIAN	DO NOT TRUST CHILD'S PEDIATRICIAN	
Skipped/delayed a vaccine besides flu/covid	16%	12%	41%	
Say childhood vaccines don't go through enough safety testing	35%	30%	62%	
Say the CDC recommends too many vaccines for children	26%	22%	55%	

Source: Source: July 18-Aug. 4, 2025, Washington Post-KFF poll of 2,716 U.S. parents and guardians of children under 18 with an error margin of +/- 2 percentage points. Error margin is larger among subgroups.

SCOTT CLEMENT / THE WASHINGTON POST

::::::

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

Organization Announcements

Paul G. Allen Frontiers Group [11 Oct 2025]

https://alleninstitute.org/news-press/

Recent News

News

Scientists fix genetic defect in mice tied to brain disorders that include autism and epilepsy Oct 9, 2025

Gene therapy successfully reduced epileptic activity, hyperactivity and risk-taking behaviors tied to SYNGAP1-related disorders

BMGF - Gates Foundation [11 Oct 2025]

https://www.gatesfoundation.org/ideas/media-center Press Releases & Statements No new digest content identified.

CARB-X [11 Oct 2025]

https://carb-x.org/

News

No new digest content identified.

Chan Zuckerberg Initiative [11 Oct 2025]

https://chanzuckerberg.com/newsroom/

Newsroom

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [11 Oct 2025]

http://cepi.net/

CEPI News, Blog

Blog

Stronger, faster, fairer: making mpox vaccines accessible

Find out more about how CEPI's mpox programme is helping to close evidence gaps for vulnerable groups so that mpox vaccines can swiftly move from the shelves to the shoulders of those who need them most.

7 Oct 2025

News

CEPI partners with AVAREF to boost clinical trial application reviews in Africa

BRAZZAVILLE/OSLO, 7 OCT—New funding to the AdVAncIng Clinical TRials Excellence in Africa (AVAREF) could help accelerate the development of life-saving vaccines to contain infectious disease outbreaks on the continent.

The Coalition for Epidemic Preparedness Innovations (CEPI) is providing \$1 million to AVAREF as part of a new two-year project to enhance the efficiency with which African regulatory agencies and ethics committees—who are already part of the AVAREF network—review and make emergency decisions on multi-country clinical trial applications...

News

CEPI backs new research into vaccines against multiple deadly filoviruses

6 Oct 2025

CIOMS - COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 11

Oct 2025]

https://cioms.ch/

News; Publications; Events

CIOMS September 2025 newsletter

DARPA – Defense Advanced Research Projects Agency [U.S.] [11 Oct 2025]

https://www.darpa.mil/news

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases initiative [11 Oct 2025]

https://dndi.org/press/press-releases/

Press Releases

No new digest content identified.

Duke Global Health Innovation Center [11 Oct 2025]

https://dukeghic.org/

News

No new digest content identified.

EDCTP [11 Oct 2025]

http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials News

No new digest content identified.

Emory Vaccine Center [11 Oct 2025]

http://www.vaccines.emory.edu/ Vaccine Center News

No new digest content identified.

European Vaccine Initiative [11 Oct 2025]

http://www.euvaccine.eu/ Latest News, Events No new digest content identified.

Fondation Merieux [11 Oct 2025]

http://www.fondation-merieux.org/

Actualités

Announcement

Dorothée Lintner appointed Director General of the Mérieux Foundation

October 1, 2025 - Lyon (France)

The Board of Directors has appointed Dorothée Lintner as Director General of the Mérieux Foundation. She will take up her post on October 1, 2025, succeeding Jean-Pierre Bosser, whose term ended at the end of September after six years of service to the Foundation and public health.

Gates Medical Research Institute [11 Oct 2025]

https://www.gatesmri.org/news

The Gates Medical Research Institute is a non-profit organization dedicated to the discovery, development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.

News: Articles and Publications No new digest content identified.

Gavi [to 11 Oct 2025]

https://www.gavi.org/

News Releases 10 October 2025

As World Health Summit gathers in Berlin, Gavi and IRC's REACH consortium deliver 20 million vaccine doses in crisis settings, reduces delivery cost per dose to US\$ 2

8 October 2025

Ghana launches HPV vaccine to protect over 2 million girls and combat cervical cancer

6 October 2025

Nigeria launches historic integrated vaccination campaign targeting 100 million children

GE2P2 Global Foundation [11 Oct 2025]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

Digests

- :: Vaccines and Global Health: The Week in Review Current edition
- :: Informed Consent: A Monthly Review May 2025
- :: Public Consultations Watch :: Global Calls for Input/Public Comment 03 Oct 2025
- :: Genomics :: Governance, Ethics, Policy, Practice A Monthly Digest May 2025

GHIT Fund [11 Oct 2025]

https://www.ghitfund.org/newsroom/press

Press Releases

No new digest content identified.

Global Fund [to 11 Oct 2025]

https://www.theglobalfund.org/en/news/

News Releases

10 October 2025

Global Fund Commends Denmark's Pledge to the Eighth Replenishment

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), commends Denmark's DKK 375 million pledge, which underscores its long-standing commitment to global health at a critical time of escalating health challenges and widening ineq...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [11 Oct 2025]

https://www.glopid-r.org/

News & Events

No new digest content identified.

Hilleman Laboratories [11 Oct 2025]

http://www.hilleman-labs.org/

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [11 Oct 2025]

https://www.hhmi.org/news

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [11 Oct 2025]

https://www.humanimmunomeproject.org/

News

No new digest content identified.

IAVI [11 Oct 2025]

https://www.iavi.org/

Press Releases, Features

Press Releases

IAVI, Minapharm, and ProBioGen Announce Memorandum of Understanding to Progress Clinical Development, Manufacturing, Commercialization, and Access to Vaccines and Antibodies in Africa

October 10, 2025

Partners will advance end-to-end development of biologics for regionally prioritized diseases starting with Mpox and HIV

INSERM [11 Oct 2025]

https://www.inserm.fr/en/home/

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

http://www.icmra.info/drupal/en/news Selected Statements, Press Releases, Research No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 11 Oct 2025]

https://www.ich.org/

News/Pubs/Press Releases [Selected]

8 October 2025

ICH E6(R3) Module 1 Training Now Available on the ICH Website

The ICH Secretariat is pleased to announce the publication of the following training module, now available in the ICH Training Library: Interpretation and Application of ICH E6(R3): Good Clinical Practice Guideline - Module 1: Introduction and

On	going Public	c Consultations	^
>	M13B EWG	Bioequivalence for Immediate-Release Solid Oral Dosage Forms	
>	Q1 EWG	Stability Testing of Drug Substances and Drug Products	
>	M4Q(R2) EV	VG Revision of M4Q(R1)	
>	E21 EWG	Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials	
>	Q3E EWG	Guideline for Extractables and Leachables	
~	E20 EWG	Adaptive Designs for Clinical Trials	

https://www.ich.org/page/public-consultations

ICH: E20 EWG Adaptive Designs for Clinical Trials

ICH Public consultation dates:

ANMAT, Argentina - Deadline for comments by 8 October 2025

EC, Europe - Deadline for comments by 30 November 2025

Health Canada, Canada - Deadline for comments by 25 September 2025

MHRA, UK - Deadline for comments by 30 November 2025

Swissmedic, Switzerland - Deadline for comments by 30 November 2025

TFDA, Chinese Taipei - Deadline for comments by 13 October 2025

USA, FDA, Deadline 12/01 2025 Docket No. FDA-2025-D-3023

The E20 EWG is working on the development of a new E20 Guideline on "Adaptive Clinical Trials" on the design, conduct, analysis, and interpretation of adaptive clinical trials that provides a transparent and harmonized set of principles for the regulatory review of these studies in a global drug development program. These principles should also provide the flexibility to evaluate / discuss innovative approaches to clinical trial design throughout the development process.

Rapporteur: Dr. Gregory Levin (FDA, United States) Regulatory Chair: Dr. Christian Roes (EC, Europe) Date of Step 2b: 25 June 2025 Status: Step 3

ICRC [to 11 Oct 2025]

https://www.icrc.org/en/news

News

Ethiopia: ICRC provides urgent medical aid and visits detainees following armed clashes in Amhara region

News release 10-10-2025

ICRC president: Ceasefire agreement offers chance to save lives, reunite families

News *release* 10-10-2025

IFFIm [11 Oct 2025] http://www.iffim.org/ Press Releases/Announcements No new digest content identified. **IFRC** [to 11 Oct 2025]

http://media.ifrc.org/ifrc/news/press-releases/

Press releases

Press release 10/10/2025

<u>Urgent humanitarian needs remain in Myanmar, over six months after devastating</u> <u>earthquakes – IFRC.</u>

Press release 09/10/2025

IFRC Governing Board Oversight Group update

IPPS - International Pandemic Preparedness Secretariat [11 Oct 2025]

https://ippsecretariat.org/news/

News

No new digest content identified.

Institut Pasteur [11 Oct 2025]

https://www.pasteur.fr/en/press-ar`ea

Press Documents

No new digest content identified.

ISC / International Science Council [to 11 Oct 2025]

https://council.science/current/

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

blog

podcast 09 October 2025 - 17 min listen

Rethinking growth and resilience in the research ecosystem

International Union of Immunological Societies (IUIS)

https://iuis.org/ News, Resources

IUIS 2025 Congress Recordings Now Available on ImmunoHub

September 30, 2025

IVAC [11 Oct 2025]

https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

Updates: Events

No new digest content identified.

IVI [11 Oct 2025]

http://www.ivi.int/

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [11 Oct 2025]

https://centerforhealthsecurity.org/newsroom Center News [Selected] No new digest content identified.

MSF/Médecins Sans Frontières [to 11 Oct 2025]

http://www.msf.org/ Latest [Selected Announcements] Gaza-Israel war

Ceasefire in Gaza: Humanitarian aid must flow immediately

10 Oct 2025

National Academy of Medicine - USA [to 11 Oct 2025]

https://nam.edu/programs/ News, Stories, Insights Oct 9, 2025 News

National Academy of Medicine Announces Five 2025–26 Fellows in State Health Policy Fellowship Program

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 11 Oct 2025]

https://www.nationalacademies.org/newsroom

News

CDC's Vaccine Safety Monitoring Office Performed Well During COVID-19 Pandemic; Steps Needed to Safeguard Office's Independence, Improve Communications

Throughout COVID-19 pandemic, CDC's Immunization Safety Office performed well and carried out scientifically robust, timely, and effective monitoring and evaluation of the safety of COVID-19 vaccines. A new National Academies report identifies steps needed to safeguard office's independence and improve communications moving forward.

Date 2025-10-07 Type News Release

PATH [11 Oct 2025]

https://www.path.org/media-center/ Newsroom [Selected] No new digest content identified.

Sabin Vaccine Institute [11 Oct 2025]

https://www.sabin.org/press/ Latest News & Press Releases No new digest content identified.

UNAIDS [11 Oct 2025]

http://www.unaids.org/en
News, Stories, Updates
No new digest content identified.

UNICEF [to 11 Oct 2025]

https://www.unicef.org/media/press-releases

Latest press releases, news notes and statements [Selected]

Statement 10 October 2025

Statement by UNICEF Executive Director Catherine Russell on the ceasefire in the Gaza Strip

NEW YORK, 10 October 2025 –, "UNICEF welcomes today's ceasefire in the Gaza Strip, which provides hope for Palestinian children who have suffered through two years of horrific war. "UNICEF has more than 1,300 trucks ready to bring in tents, nutrition items, essential medicines and vaccines, learning and recreation...

Remarks 10 October 2025

Ceasefire provides glimmer of hope for children in Gaza

GENEVA, 10 October 2025 – ", Let me begin by sharing the reaction to yesterday's news of this agreement to secure a ceasefire and end the war in the Gaza Strip from two children UNICEF spoke to in Deir al Balah, southern Gaza. Their words are far more powerful than anything I can say here today. "Maisara is 13 years old. He said: 'I felt happy the moment I heard the news...

Unitaid [11 Oct 2025]

https://unitaid.org/ Press Releases News releases

Advancing new and underused innovations to end preventable death in childbirth

05 October 2025

In recognition of the first World Postpartum Hemorrhage Day, 5 October, Unitaid joins global partners in advocating for an end to a leading cause of maternal death.

Vaccine Equity Cooperative [nee Initiative] [11 Oct 2025]

https://vaccineequitycooperative.org/news/

News

No new digest content identified.

Vaccine Confidence Project [11 Oct 2025]

http://www.vaccineconfidence.org/ News, Research and Reports No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [11 Oct 2025]

http://www.chop.edu/centers-programs/vaccine-education-center

News

October 2025 – Hepatitis B Vaccine Birth Dose and Separating MMR

Check out two videos in which Dr. Paul Offit discusses vaccines in the news: hepatitis B vaccine birth dose and separating MMR vaccine into individual components.

Wellcome Trust [11 Oct 2025]

https://wellcome.org/news/all

News. Opinion, Reports

News

Sir John Gurdon, 1933-2025

8 October 2025

A Nobel-winning scientist of great modesty and humour, John Gurdon died on 7 October. Not only did he make a discovery that laid the foundations for the field of stem cell research, he also created one of the best environments for research at the Wellcome / CRUK Gurdon Institute.

The Wistar Institute [to 11 Oct 2025]

https://www.wistar.org/news/press-releases

Press Releases

No new digest content identified.

World Bank [11 Oct 2025]

http://www.worldbank.org/en/news/all All News [Selected] No new digest content identified.

WFPHA: World Federation of Public Health Associations [11 Oct 2025]

https://www.wfpha.org/ Blog, Events No new digest content identified.

World Medical Association [WMA] [to 06 Sep 025]

https://www.wma.net/news-press/press-releases/

Press Releases

New WMA President Calls for Global Physician Solidarity, Mentorship and Primary Healthcare Advocacy

10.10.2025

World Organisation for Animal Health [OIE] [11 Oct 2025]

https://www.oie.int/
Press Releases, Statements

Statements

WOAH and FAO call on Members to strengthen global efforts to eradicate PPR

Published on 9 October 2025

<u>Peste des petits ruminants (PPR)</u> is a devastating disease that causes significant economic and animal losses. With morbidity and mortality rates reaching up to 100% in naïve populations, this highly contagious viral disease poses a severe threat to sheep, goats and certain species of wild ruminants...

To succeed, eradication efforts must follow a well-designed, coordinated strategy, supported by strong infrastructure as well as investment in the veterinary workforce. These efforts must be prioritised and recognised as an international public good through political commitment as well as resource mobilisation. FAO and WOAH urge Members to remain committed to investing in transversal approaches that strengthen veterinary services and countries' capacities to control and eradicate PPR, as well as other animal diseases. Together, we can protect livestock industries and safeguard the livelihoods of those who depend on them.

::::::

ARM [Alliance for Regenerative Medicine] [11 Oct 2025]

https://alliancerm.org/press-releases/ Selected Press Releases

No new digest announcements identified.

BIO [11 Oct 2025]

https://www.bio.org/press-releases

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [11 Oct 2025]

http://www.dcvmn.org/
News; Upcoming events

DCVMN Annual General Meeting 2025

October 29 - 31, 2025

Bali, Indonesia

ICBA – International Council of Biotechnology Associations [11 Oct 2025]

https://internationalbiotech.org/news/

News

No new digest announcements identified.

IFPMA [11 Oct 2025]

https://ifpma.org/

News, Statements [Selected]

No new digest announcements identified.

International Alliance of Patients' Organizations – IAPO [11 Oct 2025]

https://www.iapo.org.uk/news

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

https://www.igbamedicines.org/

News

No new digest announcements identified.

PhRMA [11 Oct 2025]

http://www.phrma.org/

Press Releases

No new digest announcements identified.

::::::

Vaccines/Therapeutics/Medicines - Selected Developer/Manufacturer Announcements

We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.

AstraZeneca

Press Releases

Latest

<u>AstraZeneca announces historic agreement with US Government to lower the cost of medicines for American patients</u>

10 October 2025

- :: Delivers on all four of President Trump's requests reducing cost of medicines
- :: Preserves America's role as a global powerhouse in biopharmaceuticals innovation
- :: AstraZeneca to invest \$50bn in manufacturing and R&D to support domestic sourcing

AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to \$4.5 billion, creating 3,600 new jobs

09 October 2025

Bavarian Nordic

Latest News

October 09, 2025

<u>Consortium consisting of Nordic Capital and Permira receives final regulatory approval in respect of its takeover offer to the shareholders of Bavarian Nordic</u>

October 07, 2025

Bavarian Nordic Reports Positive Topline Data for Mpox/Smallpox Vaccine in Pediatric Population

- :: Primary endpoint was met in clinical study, demonstrating a comparable safety profile and a noninferior immune response for MVA-BN in children aged 2-11 years compared to adults.
- ::Results will support filing for label extension with EMA in 2026.

BioCubaFarma - Cuba

<u>Últimas Noticias</u> - No new digest announcements identified.

Biological E

News - No new digest announcements identified.

BioNTech

Press Releases - No new digest announcements identified.

Boehringer

<u>Press Releases</u> - No new digest announcements identified.

CanSinoBIO

<u>News</u> - Website not responding at inquiry.

CIGB

<u>Latest News</u> - No new digest announcements identified.

CinnaGen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

<u>News</u> - No new digest announcements identified.

CSL Sequirus

News Releases - No new digest announcements identified.

Curevac

<u>News</u> - No new digest announcements identified.

Dailchi Sankyo

<u>Press Releases</u> - No new digest announcements identified.

Gamaleya National Center/Sputnik

<u>Latest News and Events</u> - No new digest announcements identified [Last: 09 Nov 2020] <u>https://sputnikvaccine.com/</u> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media - No new digest announcements identified.

EuBiologics, S Korea

<u>News</u> - Website not responding at inquiry.

HIPRA

<u>Press releases</u> - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified.

Merck

News releases

Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025

October 09, 2025

Nanogen

News - No new digest announcements identified.

Novartis

News - No new digest announcements identified.

Novavax

Press Releases

Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering \$25 Million Milestone Payment

GAITHERSBURG, Md., Oct. 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® to Sanofi, in the

European Union (EU) enabling Sanofi to take full responsibility for commercial and regulatory activities in the EU. The transfer triggered a milestone payment of \$25 million to Novavax and further progresses the <u>collaboration and license agreement (CLA)</u> between both companies...

Pfizer

<u>Recent Press Releases</u> - No new digest announcements identified.

R-Pharm

https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified.

Serum Institute

News & Announcements

Wednesday, October 08, 2025

SCIENCE MUSEUM [UK] receives largest International Donation to date, enabling transformation of its public spaces.

Sinopharm/WIBPBIBP

<u>News</u> - No new digest announcements identified.

Sinovac

Press Releases - No new digest announcements identified.

SK Biosciences

<u>Press Releases</u> - No new digest announcements identified.

Takeda

<u>Newsroom</u> - No new digest announcements identified.

Valneva

<u>Press Releases</u> - No new digest announcements identified.

WestVac Biopharma

<u>Media</u> - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] <u>Website</u> [No News/Announcements page identified]

::::::

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 16, 2025 Issue 3 https://www.tandfonline.com/toc/uabr21/current [Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 10: E713-767 Oct 2025

https://journalofethics.ama-assn.org/issue/diagnostic-research

Diagnostic Research

What exactly is a medical mystery? Any one condition of illness could be diagnosed, misdiagnosed, a missed diagnosis, undiagnosed, or perhaps something else. The National Institutes of Health (NIH) defines undiagnosed diseases as "long-standing symptoms or elusive medical conditions that have not been diagnosed despite extensive clinical evaluation." What is now known as the Undiagnosed Diseases Network (UDN) was a research study first established by the NIH in 2008 and is now funded by the National Institute of Neurological Disorders and Stroke. Its charge is to convene experts, conduct research on human subjects at 14 US clinic locations, forge new knowledge, and "solve the most challenging medical mysteries." UDN research subjects must apply with supporting documentation from their clinicians and health records. Fewer than half of UDN applicants are enrolled in a protocol, and, among subjects evaluated by clinician-investigators, some receive a diagnosis. This theme issue considers a range of neglected diagnostic research ethics questions and investigates ethics questions about UDN policies, practices, and public support.

American Journal of Human Genetics

Oct 02, 2025 Volume 112 Issue 10 p2251-2562 https://www.cell.com/ajhq/current This month in *The Journal*

Paul W. Hook, Alyson B. Barnes

Obesity and obesity-related traits have a major impact on global health. While a myriad of genes and variants have been associated with these traits, substantial functional work still needs to be performed to understand the underlying molecular mechanisms. In this issue, Baya et al. identify genes associated with obesity and fat distribution using exome sequencing from the UK Biobank and test their function in a human adipocyte cell line. Using rare variant gene burden tests, the authors find 69 genes associated with traits, including body mass index (BMI), waist-to-hip ratio adjusted for BMI, and body fat percentage.

[Reviewed earlier]

American Journal of Infection Control

September 2025 Volume 53 Issue 9 p919-1022 http://www.ajicjournal.org/current [Reviewed earlier]

American Journal of Preventive Medicine

September 2025 Volume 69 Issue 3 https://www.ajpmonline.org/current [Reviewed earlier]

American Journal of Public Health

October 2025 115(10) http://ajph.aphapublications.org/toc/ajph/current [Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 113 (2025): Issue 3 (Sep 2025) https://www.ajtmh.org/view/journals/tpmd/113/3/tpmd.113.issue-3.xml [Reviewed earlier]

Annals of Internal Medicine

September 2025 Volume 178, Issue 9 https://www.acpjournals.org/toc/aim/current [Reviewed earlier]

Artificial Intelligence - An International Journal

Volume 346 September 2025 https://www.sciencedirect.com/journal/artificial-intelligence/vol/346/suppl/C [New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation

http://resource-allocation.biomedcentral.com/ (Accessed 11 Oct 2025) [No new digest content identified]

BMC Health Services Research

http://www.biomedcentral.com/bmchealthservres/content (Accessed 11 Oct 2025

<u>Commonality of 25 component themes of integrated care for children: rapid review of 170 models</u>

The components of integrated care for children, young people and families (CYPF) listed across existing authoritative guidance is generally consistent; the guidance suggests a list of components that should id...

Authors: Evgenia Stepanova, Frances Hillier-Brown, Emily Owen-Boukra, Steven Hope, Steph Scott, Dougal Hargreaves, Dasha Nicholls, Russell M. Viner and Carolyn Summerbell

Citation: BMC Health Services Research 2025 25:1332

Content type: Systematic Review Published on: 8 October 2025

BMC Infectious Diseases

http://www.biomedcentral.com/bmcinfectdis/content

(Accessed 11 Oct 2025)

Hepatitis B vaccination status, knowledge and associated factors among healthcare professionals in Dongola, Sudan, 2024: a cross-sectional study

Hepatitis B virus (HBV) infection remains a significant global health concern, with 254 million people chronically infected worldwide and 1.1 million annual deaths from related complications. Healthcare profes...

Authors: Mogahid Mohamed Awad, Sami Altalib and Kamil M. Shaaban

Citation: BMC Infectious Diseases 2025 25:1279

Content type: Research Published on: 10 October 2025

Hepatitis B vaccination status, knowledge and associated factors among healthcare professionals in Dongola, Sudan, 2024: a cross-sectional study

Hepatitis B virus (HBV) infection remains a significant global health concern, with 254 million people chronically infected worldwide and 1.1 million annual deaths from related complications. Healthcare profes...

Authors: Mogahid Mohamed Awad, Sami Altalib and Kamil M. Shaaban

Citation: BMC Infectious Diseases 2025 25:1279

Content type: Research Published on: 10 October 2025

Hepatitis B vaccination status, knowledge and associated factors among healthcare professionals in Dongola, Sudan, 2024: a cross-sectional study

Hepatitis B virus (HBV) infection remains a significant global health concern, with 254 million people chronically infected worldwide and 1.1 million annual deaths from related complications. Healthcare profes...

Authors: Mogahid Mohamed Awad, Sami Altalib and Kamil M. Shaaban

Citation: BMC Infectious Diseases 2025 25:1279

Content type: Research Published on: 10 October 2025

BMC Medical Ethics

http://www.biomedcentral.com/bmcmedethics/content

(Accessed 11 Oct 2025)

Bridging ethical gaps in digital health research: a framework for informed consent aligned with NIH quidance

Digital health technologies, including mobile applications, wearable devices, and sensors, are rapidly transforming clinical research. However, current informed consent practices often fall short of addressing...

Authors: Rahma Rizky Alifia, Malihe Sadeghi, Maheswari Eluru, Mohammad Jafari and Maria Adela

Grando

Citation: *BMC Medical Ethics* 2025 26:132

Content type: Research Published on: 8 October 2025

Ethics review or compliance check? an empirical analysis of 6740 requests for information in Belgian clinical trial evaluations (2017–2024)

The EU Clinical Trials Regulation (CTR) was introduced to harmonize clinical trial evaluations across

Member States while upholding participant protection and ethical integrity. This study analyzes 6740 Requests for Information (RFIs) issued by Belgian Medical Research Ethics Committees (MRECs) across 266 trial dossiers evaluated between 2017 and 2024, spanning both the CTR pilot phase and the initial CTIS implementation.... The study also highlights a growing emphasis on regulatory compliance—sometimes at the expense of ethical deliberation—and the limited authority of policy advisors to correct inconsistencies, despite their expertise. We recommend clearer guidance, formalized roles for policy advisors in quality control, improved pre-submission processes, and limited direct communication between MRECs and sponsors. These findings support ongoing efforts to improve ethics review efficiency and quality under the CTR, with broader relevance for harmonization across Europe.

Authors: Audrey Van Scharen, Michel Deneyer and Pieter Cornu

Citation: BMC Medical Ethics 2025 26:129

Content type: Research Published on: 8 October 2025

BMC Medicine

http://www.biomedcentral.com/bmcmed/content (Accessed 11 Oct 2025) No new digest content identified]

BMC Pregnancy and Childbirth

http://www.biomedcentral.com/bmcpregnancychildbirth/content (Accessed 11 Oct 2025) No new digest content identified]

BMC Public Health

http://bmcpublichealth.biomedcentral.com/articles (Accessed 11 Oct 2025)

<u>Vaccine hesitancy among legal guardians of children with chronic neurological disorders: a cross-sectional study in Saudi Arabia</u>

Vaccine hesitancy poses a significant public health challenge, particularly among vulnerable populations such as children with chronic neurological disorders (NDDs). Despite the proven efficacy of vaccines, li...

Authors: Ahmed M. Almutairi, Ahmad A. Alanezi, Khalid A. Almahmoud, Abdulaziz M. Aljuhni, Waleed A.

Alluhidan, Tamim A. Abahussain and Khalid Alzaraa

Citation: BMC Public Health 2025 25:3429

Content type: Research Published on: 9 October 2025

Socio-demographic factors associated with incomplete vaccination or non-vaccination among children aged 12–23 months in Sierra Leone

Childhood vaccination coverage in Sierra Leone remains unsatisfactory despite multiple efforts made by health authorities to enhance collective immunity of the population, especially for children aged 12 to 23...

Authors: Dove Djossaya, Thompson Igbu, Desmond Kangbai, Innocent Nuwagira, Andrew Kemoh, Michael Jones, Tom Sesay, Sallu Lansana, Samuel Adeyemi Williams, Gbessay Saffa, Ibrahim Franklyn Kamara, Adjidja Amani, Andre Arsene Bita Fouda and Blanche Philomène Melanga Anya

Ramara, Adjuda Amari, Andre Arsche bita i odda dna bianche i mi

Citation: *BMC Public Health* 2025 25:3423

Content type: Research Published on: 9 October 2025

Effects of an educational health promotion intervention to improve human papillomavirus vaccination acceptance and uptake among adolescent girls: a cluster randomized controlled trial

Human Papillomavirus (HPV) is the most common sexually-transmitted infection worldwide and the primary cause of cervical cancer. Although timely vaccination can prevent HPV infection and reduce the risk of cer...

Authors: Suzanne Hoi Shan Lo, Janita Pak Chun Chau, Kai Chow Choi, Laveeza Butt, Grace Chung Yan

Lui, Vivian Wing Yan Lee and Alexander Yuk Lun Lau

Citation: BMC Public Health 2025 25:3419

Content type: Research Published on: 9 October 2025

<u>Trends in the global burden of childhood meningitis between 1990 and 2021 and projections to 2035: based on the global burden of diseases database 2021</u>

This study aimed to assess trends in the incidence, mortality and disability-adjusted life years (DALYs) of meningitis in children aged 0–14 years between 1990 and 2021 worldwide.

Authors: Duo-Duo Li, Xin-Quan Sang, Qian Huang, Li Wang, Yi-Shuai Ren, Li-Ping Deng, Wei-Hong Lu,

Xiang-Tao Wu, Ya-Li Xu, Xi-Xia Guo and Feng-Lian Zhu

Citation: BMC Public Health 2025 25:3404

Content type: Research Published on: 8 October 2025

Vaccination models of delivery for refugees and migrants: a global scoping review

Refugees and migrants face inequities in healthcare and vaccination access. Diverse vaccination programs have been implemented globally among refugee and migrant populations targeting vaccine hesitancy and oth...

Authors: Fariba Aghajafari, Dorota Guzek, Huzaifa Kamal, Alyssa Ness, Laurent Wall, Caitlin McClurg,

Arshya Pooladi-Darvish, Amanda M. Weightman and Annalee Coakley

Citation: BMC Public Health 2025 25:3396

Content type: Research Published on: 8 October 2025

Anti-vaccination of Turkish parents in forums: a qualitative study

Epidemics of preventable diseases are re-emerging in many parts of the world with the increasing antivaccine views and vaccine hesitancy. The purpose of this study was to analyze the themes and narratives sha...

Authors: Mehtap Gümüşay and Nevin Sahin Citation: *BMC Public Health* 2025 25:3374

Content type: Research Published on: 8 October 2025

BMC Research Notes

http://www.biomedcentral.com/bmcresnotes/content (Accessed 11 Oct 2025) [No new digest content identified]

BMJ Evidence-Based Medicine

October 2025 - Volume 30 - 5 https://ebm.bmj.com/content/30/5 [Reviewed earlier]

BMJ Global Health

October 2025 - Volume 10 - 10

https://gh.bmj.com/content/10/10

[Reviewed earlier]

Bulletin of the Atomic Scientists

DIGITAL MAGAZINE - September 2025 https://thebulletin.org/magazine/2025-09/#post-heading [Reviewed earlier]

Bulletin of the World Health Organization

Volume 103, Number 10, October 2025, 577-640 https://www.who.int/publications/journals/bulletin/

<u>Associations between digital maturity in health and primary health care performance, 109 countries.</u>

Kan L, et al.

Bull World Health Organ. 2025.

PMCID: PMC12477510

A simulation-based policy analysis of anticipatory action for cholera outbreaks, Democratic Republic of the Congo.

Loo PS, et al.

Bull World Health Organ. 2025.

PMCID: PMC12477517

Ethical clinical trial design and differences in treatment effects.

Lewis RJ, et al.

Bull World Health Organ. 2025.

PMCID: PMC12477512

Climate change and increased risk of respiratory infections in humans.

Abrescia N, et al.

Bull World Health Organ. 2025.

PMCID: PMC12477514

١

<u>Implementation of the WHO Pandemic Agreement.</u>

Jon W

Bull World Health Organ. 2025.

PMCID: PMC12481221

Conclusion

The WHO Pandemic Agreement, with its mechanisms to encourage technology transfer and benefit sharing, represents a monumental achievement in the evolution of global health law. The Agreement rightly identifies the transfer of practical know-how, not just patent rights, as the key to achieving genuine equity in pandemic response. However, the potential codified in its text is severely challenged by the realities of its implementation environment. The procedural dependency on the 2026 annex negotiation creates a critical point of delay. More profoundly, the geopolitical fractures marked by the nonparticipation and abstention of key countries threaten to undermine its core principles by fragmenting private sector engagement and global supply chains. The capacity of the Parties to overcome this implementation challenge and to bridge the divide between the Pandemic Agreement's ambitious goals and a fragmented geopolitical landscape will ultimately determine whether the Agreement can truly reshape the global response to future pandemics.

Future research should examine how enforcement mechanisms can be strengthened without compromising sovereignty, and how the Agreement's provisions might adapt to emerging technologies such as artificial intelligence-driven drug discovery platforms and mRNA platform technologies for rapid vaccine development.

Cell

Oct 02, 2025 Volume 188 Issue 20 p5433-5784

https://www.cell.com/cell/current

Bronze Age *Yersinia pestis* genome from sheep sheds light on hosts and evolution of a prehistoric plague lineage

Ian Light-Maka, et al.

A Yersinia pestis genome from a Bronze Age domesticated sheep provides insight into the host range, evolution, and possible transmission scenarios of an ancient lineage of the plague-causing bacteria, previously identified exclusively in ancient humans.

Cell and Gene Therapy Insights

May 2025 Issue Volume 11 Issue 4 https://www.insights.bio/cell-and-gene-therapy-insights/journal/250/volume-11-issue-4 [Reviewed earlier]

Child Care, Health and Development

Volume 51, Issue 6 November 2025 https://onlinelibrary.wiley.com/toc/13652214/current [New issue; No digest content identified]

Clinical Pharmacology & Therapeutics

Volume 118, Issue 4 Pages: 749-966 October 2025 https://ascpt.onlinelibrary.wiley.com/toc/15326535/current Perspective

Evidence Generation for Drugs and Biological Products isn't Magic or Myth

John Concato, Leonard Sacks, Peter Stein, Jacqueline Corrigan-Curay

Pages: 769-771

First Published: 29 July 2025

Review

<u>Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and</u> Remaining Challenges

D. Max Smith, Michael P. Douglas, Christina L. Aquilante, Patricia A. Deverka, Beth Devine, Henry M. Dunnenberger, Philip E. Empey, Daniel L. Hertz, Andrew A. Monte, Ann M. Moyer, Jai N. Patel, Victoria M. Pratt, Loren Saulsberry, Stuart A. Scott, Deepak Voora, Erica L. Woodahl, Michelle Whirl-Carrillo, Akinyemi Oni-Orisan, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee

Pages: 778-789

First Published: 04 June 2025

Clinical Therapeutics

October 2025 Volume 47 Issue 10 p827-956

http://www.clinicaltherapeutics.com/current

[New issue; No digest content identified]

Clinical Trials

Volume 22 Issue 5, October 2025 https://journals.sagepub.com/toc/ctja/22/5 [Reviewed earlier]

Conflict and Health

http://www.conflictandhealth.com/ [Accessed 11 Oct 2025] [No new digest content identified]

Contemporary Clinical Trials

Volume 157 October 2025 https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/157/suppl/C [New issue; No digest content identified]

The CRISPR Journal

Volume 8, Issue 4 / August 2025 https://www.liebertpub.com/toc/crispr/8/4 [Reviewed earlier]

Current Genetic Medicine Reports

Volume 13, Issue 1 December 2025 https://link.springer.com/journal/40142/volumes-and-issues/13-1 [Reviewed earlier]

Current Medical Research and Opinion

Volume 41, Issue 3 2025 https://www.tandfonline.com/toc/icmo20/current [Reviewed earlier]

Current Opinion in Infectious Diseases

October 2025 - Volume 38 - Issue 5 https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx PAEDIATRIC AND NEONATAL INFECTIONS [Reviewed earlier]

Current Protocols in Human Genetics

https://currentprotocols.onlinelibrary.wiley.com/journal/19348258 [Accessed 11 Oct 2025] [No new digest content identified]

Cytotherapy

October 2025 Volume 27 Issue 10 p1151-1270 https://www.isct-cytotherapy.org/current [Reviewed earlier]

Developing World Bioethics

Volume 25, Issue 3 Pages: 165-252 September 2025 https://onlinelibrary.wiley.com/toc/14718847/current [Reviewed earlier]

Development in Practice

Volume 35, Issue 5, 2025 https://www.tandfonline.com/toc/cdip20/35/5?nav=tocList [Reviewed earlier]

Development Policy Review

Volume 43, Issue 5 September 2025 https://www.tandfonline.com/toc/cdip20/35/5?nav=tocList [Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 19 - 2025

https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue

[Reviewed earlier]

Disasters

Volume 49, Issue 4 October 2025 https://onlinelibrary.wiley.com/toc/14677717/current **Future of humanitarian and development aid**[Reviewed earlier]

eBioMedicine

Volume 119 September 2025 https://www.sciencedirect.com/journal/ebiomedicine/vol/119/suppl/C [Reviewed earlier]

EMBO Reports

Volume 26 Issue 198 October 2025 https://www.embopress.org/toc/14693178/current [Reviewed earlier]

Emerging Infectious Diseases

Volume 31, Number 9—September 2025 http://wwwnc.cdc.gov/eid/ [Reviewed earlier]

Epidemics

Volume 52 September 2025 https://www.sciencedirect.com/journal/epidemics/vol/52/suppl/C [Reviewed earlier]

Epidemiology and Infection

Volume 153 - 2025

https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue [Reviewed earlier]

Ethics & Human Research

Volume 47, Issue 5 Pages: 1-43 September–October 2025 https://onlinelibrary.wiley.com/toc/25782363/current Articles

Research Participant Bill of Rights: Clarifying the Role of Research Physicians

Mark A. Rothstein Pages: 29-36

First Published: 27 September 2025 Essay: Ethics in Translational Research

<u>Translational Genomics and Community-Driven Research in Australia</u> Fiona Russo, Keri Finlay, Isabella Sherburn, Tiffany Boughtwood, Jane Tiller

Pages: 37-43

First Published: 27 September 2025

Ethics & International Affairs

Volume 39 - Issue 2 - Summer 2025

https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue

Roundtable: Global Governance in Hard Times

The Institutional Dynamics of Global Governance in Hard Times: Innovation or Decline?

Benjamin Faude, John Karlsrud

Published online by Cambridge University Press:

22 August 2025, pp. 114-129

Ethics, Medicine and Public Health

Volume 32 2024

https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc [Reviewed earlier]

The European Journal of Public Health

Volume 35, Issue 4, August 2025 https://academic.oup.com/eurpub/issue/35/4 [Reviewed earlier]

Expert Review of Vaccines

Volume 24, 2025 Issue 1 https://www.tandfonline.com/toc/ierv20/current [Reviewed earlier]

Foreign Affairs

July/August 2025 Volume 104, Number 4 https://www.foreignaffairs.com/issues/2025/104/4 [Reviewed earlier]

Forum for Development Studies

Volume 52, 2025 - Issue 2

http://www.tandfonline.com/toc/sfds20/current

The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities [Reviewed earlier]

Frontiers in Genetics

https://www.frontiersin.org/journals/genetics [Accessed 11 Oct 2025] *Editorial* Published on 09 Oct 2025

Editorial: Application of next-generation sequencing in clinical settings

Zhi Chai, et al.

Frontiers in Genetics doi 10.3389/fgene.2025.1700975

Editorial

Published on 08 Oct 2025

<u>Editorial: Genetics and justice: the implications of large-scale genome sequencing initiatives in the global south</u>

Michel Satya Naslavsky, et al. Frontiers in Genetics doi 10.3389/fgene.2025.1703507

Frontiers in Genome Editing

https://www.frontiersin.org/journals/genome-editing [Accessed 11 Oct 2025] [No new digest content identified]

Frontiers in Medicine

https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463
[Accessed 11 Oct 2025]
Original Research
Accepted on 11 Oct 2025

BLOCKCHAIN-ENABLED QUALITY BY DESIGN SYSTEM FOR CLINICAL TRIALS

Reza Vatankhah Barenji, eza Ebrahimi Hariry Frontiers in Medicine doi 10.3389/fmed.2025.1546897

Review

Accepted on 06 Oct 2025

The Future of Pediatric Gene Therapy: CRISPR-Cas9, AI, and Personalized Medicine

Yinping Pan, et al. Frontiers in Medicine doi 10.3389/fmed.2025.1690225

Gene Therapy – Nature

Volume 32 Issue 4, July 2025 https://www.nature.com/gt/volumes/32/issues/4 [Reviewed earlier]

Genetics in Medicines

Volume 27, Issue 6 June 2025 https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/65 [Reviewed earlier]

Genome Medicine

https://genomemedicine.biomedcentral.com/articles [Accessed 11 Oct 2025] [No new digest content identified]

Global Health Action

Volume 18, Issue 1 (2025) https://www.tandfonline.com/toc/zgha20/current?nav=tocList [Reviewed earlier]

Global Health: Science and Practice (GHSP)

August 2025 | Volume 13 | Number 1 http://www.ghspjournal.org/content/current [Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

https://www.loc.gov/collections/global-legal-monitor/ https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc [Accessed 11 Oct 2025]

Global Public Health

[No new digest content identified]

Volume 20, Issue 1 (2025) http://www.tandfonline.com/toc/rgph20/current [Reviewed earlier]

Globalization and Health

http://www.globalizationandhealth.com/ [Accessed 11 Oct 2025] [No new digest content identified]

Health and Human Rights

Volume 27, Issue 1, June 2025 https://www.hhrjournal.org/volume-27-issue-1-june-2025/ SPECIAL SECTION - FIGHT FOR RIGHTS VIEWPOINT SERIES

Health Economics, Policy and Law

Volume 20 - Issue 3 - July 2025 https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue [Reviewed earlier]

Health Policy and Planning

Volume 40, Issue 8, September 2025 https://academic.oup.com/heapol/issue/40/8 [Reviewed earlier]

Health Research Policy and Systems

http://www.health-policy-systems.com/content [Accessed 11 Oct 2025] [No new digest content identified]

Human Gene Therapy

Volume 36, Issue 17-18 / September 2025 https://www.liebertpub.com/toc/hum/36/17-18 Reviews

The Coming of Age of Gene Therapy for the Treatment of Human Diseases: A Regulatory Perspective

Laura Rodríguez, ... See all authors

Pages:1103-1117

Published Online: 22 August 2025

https://doi.org/10.1177/10430342251372047

Regulatory Strategies for Accelerating the Translation of Gene Therapies to Clinical

<u>Practice: Focus on GMO Considerations</u> Joaquin Delgadillo, ... See all authors

Pages:1154-1158

Published Online:21 August 2025

https://doi.org/10.1177/10430342251372063

Humanitarian Practice Network

https://odihpn.org/
[Accessed 11 Oct 2025]
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 21 Issue 1, 2025 https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList Selected Content [Reviewed earlier]

Immunity

Sep 09, 2025 Volume 58 Issue 9 p2139-2354 https://www.cell.com/immunity/current [Reviewed earlier]

Infectious Agents and Cancer

http://www.infectagentscancer.com/ [Accessed 11 Oct 2025] [No new digest content identified]

Infectious Diseases of Poverty

http://www.idpjournal.com/content]
[Accessed 11 Oct 2025]
[No new digest content identified]

International Health

Volume 17, Issue 5, September 2025 https://academic.oup.com/inthealth/issue/17/5 [Reviewed earlier]

International Human Rights Law Review

Volume 14 (2025): Issue 1 (Jun 2025) https://brill.com/view/journals/hrlr/14/1/hrlr.14.issue-1.xml [Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 12 No. 9 (2025): September 2025 https://www.ijcmph.com/index.php/ijcmph/issue/view/128 [Reviewed earlier]

International Journal of Epidemiology

Volume 54, Issue 3, June 2025 https://academic.oup.com/ije/issue/54/3 [Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 18, Issue 3 4 September 2025 https://www.emerald.com/ijhrh/issue/18/3 *Table of contents*[New issue; No digest content identified]

JAMA

October 7, 2025, Vol 334, No. 13, Pages 1129-1210 https://jamanetwork.com/journals/jama/currentissue Viewpoint

Revisiting the FDA's Accelerated Approval Pathway

Asha Kodan, MD; Joseph T. Kannarkat, MD, MPP; G. Caleb Alexander, MD, MS *JAMA*. 2025;334(13):1139-1140. doi:10.1001/jama.2025.14052

This article discusses key components of the FDA's recent guidance and suggests how the FDA could clarify expectations for confirmatory trials and management of uncertainty regarding product safety.

JAMA Health Forum

October 2025, Vol 6, No. 10 https://jamanetwork.com/journals/jama-health-forum/issue
JAMA Forum

<u>Assault on the Centers for Disease Control and Prevention—Budget Cuts, Political Control,</u> and the Erosion of Trust

Lawrence O. Gostin, JD; Peter Lurie, MD, MPH open access

JAMA Health Forum. 2025;6(10):e255467. doi:10.1001/jamahealthforum.2025.5467

The Centers for Disease Control and Prevention (CDC) has long served as the cornerstone of the US public health system, combining technical expertise, evidence-based policy recommendations, and high-quality health information. Yet, it is undergoing profound weakening by the Trump administration, including major funding cuts, the dismissal and resignation of experienced senior staff, and the erosion of its scientific independence. With tightening political control, public trust in the CDC is diminishing. Undermining the agency's reputation and capacities will reverberate for generations, making the nation less prepared for future health emergencies, including diseases of pandemic potential. At this perilous moment, we document the current assault on the CDC that will inevitably have serious repercussions for the nation's health...

Most-Favored-Nation Drug Pricing—How Courts Could Shape Future Health Regulation

Nicholas Bagley, JD; Craig Garthwaite, PhD; Benedic Ippolito, PhD JAMA Health Forum. 2025;6(10):e255440. doi:10.1001/jamahealthforum.2025.5440 This Viewpoint discusses legal questions around the Trump administration's recent Executive Order about most-favored-nation drug pricing in the US.

JAMA Pediatrics

October 2025, Vol 179, No. 10, Pages 1051-1136

https://jamanetwork.com/journals/jamapediatrics/currentissue

Viewpoint

Facing the Next Generation of US Newborn Screening

Hadley Stevens Smith, PhD, MPSA; Matthew P. Motta, PhD

JAMA Pediatr. 2025;179(10):1053-1054. doi:10.1001/jamapediatrics.2025.2582

This Viewpoint discusses the critical role of the Advisory Committee on Heritable Disorders in Newborns and Children and the importance of continued national guidance to the future of US newborn screening.

JBI Evidence Synthesis

October 2025 - Volume 23 - Issue 10

https://journals.lww.com/jbisrir/Pages/currenttoc.aspx

Editorial

<u>Economic evaluation synthesis: time for a methodological update to support equitable</u> decision-making

Jadotte, Yuri; John, Denny; Lockwood, Suzy; More

JBI Evidence Synthesis. 23(10):1895-1897, October 2025.

<u>Structured evidence summaries designed to inform decision-makers in health research: a scoping review protocol</u>

Auladell-Rispau, Ariadna; Khabsa, Joanne; Pollock, Danielle; More JBI Evidence Synthesis. 23(10):2083-2090, October 2025.

<u>Measures of shared decision-making for multiple long-term condition consultations: a scoping review protocol</u>

Butterworth, Joanne; Mattick, Karen; Richards, Suzanne; More JBI Evidence Synthesis. 23(10):2139-2147, October 2025.

Journal of Adolescent Health

October 2025 Volume 77 Issue 4 p587-796

https://www.jahonline.org/current

Original Articles

<u>TeenVac.org: A Mobile Web App to Improve Human Papillomavirus Vaccine Uptake for Adolescent Boys</u>

W. Gill Woodall, et al.

Published online: August 18, 2025

p749-755

Journal of Artificial Intelligence Research

Vol. 83 (2025)

https://www.jair.org/index.php/jair

[Reviewed earlier]

Journal of Bioethical Inquiry

Volume 22, Issue 1 March 2025

https://link.springer.com/journal/11673/volumes-and-issues/22-1

[Reviewed earlier]

Journal of Community Health

Volume 50, Issue 5 October 2025 https://link.springer.com/journal/10900/volumes-and-issues/50-5 Articles [Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 8 No. 01 (2025)

https://www.cmro.in/index.php/jcmro/issue/view/91

[Reviewed earlier]

Journal of Development Economics

Volume 176 September 2025 https://www.sciencedirect.com/journal/journal-of-development-economics/vol/176/suppl/C [Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 20 Issue 4, October 2025 http://journals.sagepub.com/toc/jre/current [Reviewed earlier]

Journal of Epidemiology & Community Health

September 2025 - Volume 79 - 9 https://jech.bmj.com/content/79/9 [Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 18, Issue 3 September 2025 https://onlinelibrary.wiley.com/toc/17565391/current [New issue; No digest content identified]

Journal of Global Ethics

Volume 21, Issue 2 (2025) http://www.tandfonline.com/toc/rjge20/current [Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 36, Number 3, August 2025 https://muse.jhu.edu/issue/55342 Table of Contents [New issue; No digest content identified]

Journal of Immigrant and Minority Health

Volume 27, Issue 4 August 2025 https://link.springer.com/journal/10903/volumes-and-issues/27-4 [Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 23, Issue 3 (2025) https://www.tandfonline.com/toc/wimm20/current [Reviewed earlier]

Journal of International Development

Volume 37, Issue 6 Pages: 1-1404 August 2025 https://onlinelibrary.wiley.com/toc/10991328/current [Reviewed earlier]

Journal of Medical Ethics

October 2025 - Volume 51 - 10 http://jme.bmj.com/content/current Original research

Ethical reflection of Chinese scientists on the dual-use concerns of emerging medical biotechnology (6 December, 2024)

Xiaonan Wang, Mingtao Huang, Hui Shao, Kun Li, Xiaomei Zhai

When understanding fails: how diverging norms in medicine and research led to informed consent failures during the pandemic (18 December, 2024)

Daniel Pinto

Navigating the consent river: questions to consider before waiving consent requirements in pragmatic cluster randomised trials (18 December, 2024)

Cory E Goldstein, Monica Taljaard, Stephanie N Dixon, Charles Weijer

Extended essays

Genetic research and the collective good: participants as leaders to reconcile individual and public interests (6 September, 2023)

Ilaria Galasso, Susi Geiger

Journal of Patient-Centered Research and Reviews

Volume 12, Issue 3 (2025) https://institutionalrepository.aah.org/jpcrr/ [Reviewed earlier]

The Journal of Pediatrics

Volume 284 September 2025 https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/284/suppl/C [Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 18, 2025 Issue 1 https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList [Reviewed earlier]

Journal of Public Health Management & Practice

September/October 2025 - Volume 31 - Issue 5 https://journals.lww.com/jphmp/pages/currenttoc.aspx [New issue; No digest content identified]

Journal of Public Health Policy

Volume 46, Issue 3 September 2025 https://link.springer.com/journal/41271/volumes-and-issues/46-3 [Reviewed earlier]

Journal of the Royal Society - Interface

October 2025 Volume 22 Issue 231 https://royalsocietypublishing.org/toc/rsif/current [Reviewed earlier]

Journal of Travel Medicine

Volume 32, Issue 6, August 2025 https://academic.oup.com/jtm/issue [Reviewed earlier]

Journal of Virology

Volume 99 • Number 6 • June 2025 http://jvi.asm.org/content/current [Reviewed earlier]

The Lancet

Oct 11, 2025 Volume 406 Number 10512 p1535-1700, e29 https://www.thelancet.com/journals/lancet/issue/current Editorial

Reclaiming care in the age of AI

The Lancet

60 years ago, the patient—doctor interaction was, at its best, about human beings connecting, engaging, listening, observing, and caring. Notes and letters were written by hand or typed afterwards, placed in an envelope, and sent by post. Later, notes were dictated into handheld tape recorders and typed up by medical secretaries, then by patchy automated dictation tools. Emails were introduced and patient data were entered into a multitude of poorly integrated systems. These developments occurred alongside important movements for patient safety, an increasingly litigious environment, the industrialisation and commercialisation of most health-care interactions, and the proliferation of medical

evidence. The leviathan that is clinical administrative work was born. Although its purpose is crucial, the sheer scale of this work has had a blunting effect on the human, caring part of health care....

Care of an individual begins and ends with a human being. AI can help that person be seen more clearly—free from the noise of paperwork, distraction, and exhaustion. The next phase of progress in health care will depend less on technical capacity and more on ethical stewardship and the health-care community's ability to keep humans at the centre of design and deployment. If done properly, AI will not replace care; rather, it could help us rediscover it.

The Lancet Commissions

The EAT—Lancet Commission on healthy, sustainable, and just food systems Johan Rockström, et al.

The Lancet Child & Adolescent Health

Oct 2025 Volume 9 Number 10 p685-752 https://www.thelancet.com/journals/lanchi/issue/current [Reviewed earlier]

Lancet Digital Health

Aug 2025 Volume 7 Number 8 https://www.thelancet.com/journals/landig/issue/current [Reviewed earlier]

Lancet Global Health

Oct 2025 Volume 13 Number 10 e1654-e1780 https://www.thelancet.com/journals/langlo/issue/current Comment

<u>Monitoring the benefits of human papillomavirus vaccination in low-income and middle-income countries</u>

Cyra Patel, Julia Brotherton

A new era for Africa's leadership: driving health sovereignty, financing, and equity Kadidiatou Toure, Etienne Langlois, Desta Lakew

Articles

Effects of reductions in US foreign assistance on HIV, tuberculosis, family planning, and maternal and child health: a modelling study

John Stover, et al.

Effect of Brazil's national human papillomavirus vaccination programme on the incidence of cervical cancer and cervical intraepithelial neoplasia grade 3 in women aged 20–24 years: a population-based study

Thiago Cerqueira-Silva, Manoel Barral-Netto, Viviane Sampaio Boaventura

Sustained efficacy of the RTS,S/AS01_E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial

Lawrence Osei-Tutu, et al.

Routine immunisation coverage in the context of seasonal influenza vaccine introduction for children in Nakuru and Mombasa counties in Kenya, 2019–21: an observational study Ledor S Igboh, et al.

Lancet Infectious Diseases

Sep 2025 Volume 25 Number 9 p947-1054, e491-e541 https://www.thelancet.com/journals/laninf/issue/current [Reviewed earlier]

Lancet Public Health

Oct 2025 Volume 10 Number 10 e804-e88 https://www.thelancet.com/journals/lanpub/issue/current [Reviewed earlier]

Lancet Respiratory Medicine

Sep 2025 Volume 13 Number 9 p769-856, e45-e52 https://www.thelancet.com/journals/lanres/issue/current [Reviewed earlier]

Maternal and Child Health Journal

Volume 29, Issue 10 October 2025 https://link.springer.com/journal/10995/volumes-and-issues/29-10 [Reviewed earlier]

Medical Decision Making (MDM)

Volume 45 Issue 7, October 2025 http://mdm.sagepub.com/content/current [Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy Volume 103, Issue 3 Pages: 639-939 September 2025 https://onlinelibrary.wiley.com/toc/14680009/current [Reviewed earlier]

Molecular Therapy

Oct 01, 2025 Volume 33 Issue 10 p4657-5282 https://www.cell.com/molecular-therapy/current In this issue

The advent of mRNA vaccines has revolutionized vaccine development, offering a swift and versatile development platform. One advantage possessed by mRNA vaccines is the ability to express antigens in soluble/secreted forms or transmembrane (TM) forms, which can better mimic the native viral envelope (Env) protein. Previous research has indicated some improvements in immune responses with the use of a TM Env trimer immunogen over the use of a secreted antigen, but the picture of the impact of TM antigens on the full immune response has remained incomplete.

Nature

Volume 646 Issue 8084, 9 October 2025 https://www.nature.com/nature/volumes/646/issues/8084 Editorial

Weaponizing uncertainty in science and in public health puts people in harm's way

Those who cite scientific studies to support policies should take care to tell the whole story, especially when it's complex.

Editorial 03 Oct 2025

... In public health, as in science more broadly, decisions are made by regularly assessing all of the available evidence, taking into account the quality of studies, and not just by citing those statements that support one view over others. If new evidence emerges, recommendations are reconsidered and, if necessary, revised. That is how the world's public-health bodies operate because they agree there is, for now, no better way to improve health care and reduce risks. The fact that the US federal agencies are now moving away from this approach poses real dangers to the health of people living there and around the world.

Public-health bodies everywhere must continue to correct the record, and do so quickly when required. The risks of inaction are too great. In science, there is almost always uncertainty. The responsible thing to do is communicate studies in a way that represents the fullness of their findings; and in public health to ensure that decisions are made in line with the consensus of experts.

Nature Biotechnology

Volume 43 Issue 9, September 2025 https://www.nature.com/nbt/volumes/43/issues/9 [Reviewed earlier]

Nature Communications

https://www.nature.com/subjects/health-sciences/ncomms (Accessed 11 Oct 2025) [Reviewed earlier]

Nature Genetics

Volume 57 Issue 10, October 2025 https://www.nature.com/ng/volumes/57/issues/10 Comment

Realizing the full potential of Our Future Health through data linkage and trans-biobank efforts

The scale and population coverage of Our Future Health, alongside other next-generation biobanks, offers unique opportunities to advance genomic medicine. Focusing on the UK context, we provide a researcher's perspective of how this new resource could reach its full potential in a way that is impactful, user-friendly and informs related global efforts.

Vincent J. Straub, Stefania Benonisdottir, Melinda C. Mills Comment 15 Sept 2025

Perspectives

<u>The Solve-RD Solvathons as a pan-European interdisciplinary collaboration to diagnose patients with rare disease</u>

This Perspective presents the Solve-RD Solvathon model, an innovative, pan-European framework uniting clinical and bioinformatics experts to diagnose rare diseases through integrative multiomics analysis and structured collaboration.

Vicente A. Yépez, German Demidov, Holm Graessner Perspective 09 Sept 2025

<u>Population-scale gene-based analysis of whole-genome sequencing provides insights into metabolic health</u>

Analyses of whole-genome sequencing data from UK Biobank and All of Us identify rare variant burden signals associated with metabolic health, including effects of protein-truncating variants in IRS2 on type 2 diabetes and chronic kidney disease risk.

Yajie Zhao, Sam Lockhart, John R. B. Perry Article Open Access 10 Oct 2025

A multi-tissue single-cell expression atlas in cattle

This study introduces the Cattle Cell Atlas, a single-cell expression resource including 1,793,854 cells from 59 tissues. Integrative analyses leveraging this atlas provide insights into the biology underlying bovine monogenic and complex traits.

Bo Han, Houcheng Li, Dongxiao Sun Article Open Access 05 Sept 2025

Genetic variants affecting RNA stability influence complex traits and disease risk

RNAtracker is a computational pipeline that distinguishes variants associated with allele-specific RNA stability from those associated with allele-specific RNA transcription. Variants affecting RNA stability are enriched in immune-related genes and contribute to disease risk.

Elaine Huang, Ting Fu, Xinshu Xiao Article 05 Sept 2025

Nature Human Behaviour

Volume 9 Issue 8, August 2025 https://www.nature.com/nathumbehav/volumes/9/issues/8 [Reviewed earlier]

Nature Medicine

Volume 31 Issue 9, September 2025 https://www.nature.com/nm/volumes/31/issues/9 [Reviewed earlier]

Nature Reviews Drug Discovery

Volume 24 Issue 10, October 2025 https://www.nature.com/nrd/volumes/24/issues/10

Innovative Medicines Initiative public-private partnerships to enhance translational safety

Innovative Medicines Initiative projects focused on translational safety have developed a range of tools to improve preclinical assessments of potential drug toxicities, and demonstrated the value of integrating data from multiple companies.

Salah-Dine Chibout, Dominique Brees, Elisabetta Vaudano Comment 22 May 2025

New US\$3.1 billion foundation takes big, long-term bets on bioscience, AI and the environment

Lynda Stuart, president and CEO of the newly launched Fund for Science and Technology, discusses the philanthropic organization's plans for bioscience and AI.

Asher Mullard

An Audience With 12 Sept 2025

The rise of China's pharmaceutical industry from 2015–2024: a decade of innovation

Sen Liu, Hongxi Hu Xiaoyuan Chen From the Analyst's Couch 21 Jul 2025

Nature Reviews Genetics

Volume 26 Issue 10, October 2025

https://www.nature.com/nrg/volumes/26/issues/10

Making sense of the regulatory genome

For the 25th anniversary of Nature Reviews Genetics, we reflect on exciting progress towards decoding the regulatory genome and its mechanisms, a central goal in genetics that must be solved with interdisciplinary research to yield widespread insights into evolution, development and disease. *Editorial* 16 Sept 2025

Regulatory genomics at biobank scales

Studies of human regulatory genomics are being performed at biobank scales, with data from tens of thousands of individuals. Stephen Montgomery describes how these datasets will advance our understanding of how variation in gene regulation shapes human traits and disease.

Stephen B. Montgomery

Comment 16 Sept 2025

Predicting the regulatory genome

In this Comment, the authors overview the latest deep learning models for predicting regulatory function from genomic sequence and highlight key topics going forward, including the trade-off between specialized and general models, multitasking across cell types, and training on genetic variation and diverse species.

Sarthak Tiwari, Alireza Karbalayghareh, Christina S. Leslie

Perspectives

Tracing the evolution of sequencing into the era of genomic medicine

Extraordinary advances in genomic science have defined the twenty-first century, transforming our understanding of human biology in both health and disease. This timeline Perspective charts two decades of genomic innovation since the human genome reference sequence became available, highlighting the evolution of sequencing technologies and how they, combined with computational advances, paved the way for genomic medicine.

Elaine R. Mardis, Richard K. Wilson

Nature Reviews Immunology

Volume 25 Issue 8, August 2025 https://www.nature.com/nri/volumes/25/issues/8 [Reviewed earlier] Volume 393 No. 14 October 9, 2025

https://www.nejm.org/toc/nejm/medical-journal

Original Article

Permethrin-Treated Baby Wraps for the Prevention of Malaria

R.M. Boyce and Others

Malaria remains a major cause of childhood death in sub-Saharan Africa. We leveraged the traditional practice of mothers carrying children on their backs in cloth wraps to assess whether treating the wraps with an insect repellent might provide a layer of protection against malaria...Among mother—child pairs who had access to bed nets, maternal use of permethrin-treated baby wraps significantly reduced the incidence of clinical malaria in the children. (Funded by the Doris Duke Foundation and others; ClinicalTrials.gov number, NCT05391230.)

NEJM Evidence

Volume 4 No. 9 September 2025

https://evidence.nejm.org/toc/evid/current

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

https://www.nature.com/npjvaccines/ [Accessed 11 Oct 2025] [No new digest content identified]

Pediatrics

Volume 156, Issue 4 October 2025 https://publications.aap.org/pediatrics/issue/156/3 Articles

<u>HIV Preexposure Prophylaxis Prescriptions, Consent Laws, and Uptake Barriers Among Adolescents</u>

Erika G. Martin, PhD MPH; Montserrat Avila Acosta, MA; Dawn A. Pepin, JD MPH; Ya-lin A. Huang, PhD; Weiming Zhu, MD PhD ...

PharmacoEconomics

Volume 43, Issue 10 October 2025 https://link.springer.com/journal/40273/volumes-and-issues/43-10 [Reviewed earlier]

PLoS Biology

https://journals.plos.org/plosbiology/ (Accessed 11 Oct 2025) [No new digest content identified]

PLoS Genetics

https://journals.plos.org/plosgenetics/ (Accessed 11 Oct 2025)

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE NEWEST FIRST&filterStartDate=2 021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60 (Accessed 11 Oct 2025)

<u>Targeted vaccination is effective for mpox clade Ib in England despite increased household</u> transmission: Predictions from a modelling study

Ellen Brooks-Pollock, Leon Danon Research Article | published 08 Oct 2025 PLOS Global Public Health https://doi.org/10.1371/journal.pgph.0005188

PLoS Medicine

https://journals.plos.org/plosmedicine/ (Accessed 11 Oct 2025) [No new digest content identified]

PLoS Neglected Tropical Diseases

http://www.plosntds.org/ (Accessed 11 Oct 2025)

Barriers to rabies control through mass dog vaccination in rural Uganda: Insights from community perspectives and key informant interviews

Dickson Akankwatsa, Arthur Bagonza, Juliet Kiguli, Andrew Kambugu, Mohammed Lamorde, Samuel George Okech, Clovice Kankya, Doreen Agado, Felister Apio, Terence Odoch, Anna Mary Kahunde, Sonja Hartnack, Monique Léchenne, Frederic Lohr, Adrian Herrera, Salome Dürr Research Article | published 09 Oct 2025 PLOS Neglected Tropical Diseases https://doi.org/10.1371/journal.pntd.0013578

PLoS One

http://www.plosone.org/
[Accessed 11 Oct 2025]
[No new digest content identified]

PLoS Pathogens

http://journals.plos.org/plospathoge ns/ [Accessed 11 Oct 2025] [No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

October 7, 2025 vol. 122 no. 40 https://www.pnas.org/toc/pnas/122/40 *Editorial* October 1, 2025

<u>Current progress and research needs to protect children's environmental health</u> Katherine L. O'Shaughnessy, et al.

PNAS Nexus

Volume 4, Issue 9, September 2025

https://academic.oup.com/pnasnexus/issue/4/9

Applied Mathematics

<u>Ideological fragmentation of the social media ecosystem: From echo chambers to echo platforms</u>

Edoardo Di Martino and others

PNAS Nexus, Volume 4, Issue 9, September 2025, pgaf262,

https://doi.org/10.1093/pnasnexus/pgaf262

Prehospital & Disaster Medicine

Volume 40 - Issue 3 - June 2025

https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue [Reviewed earlier]

Preventive Medicine

Volume 198 September 2025 https://www.sciencedirect.com/journal/preventive-medicine/vol/198/suppl/C [Reviewed earlier]

Proceedings of the Royal Society B

October 2025 Volume 292 Issue 2056

https://royalsocietypublishing.org/toc/rspb/current

[New issue; No digest content identified]

Public Health

Volume 246 September 2025 https://www.sciencedirect.com/journal/public-health/vol/246/suppl/C [Reviewed earlier]

Public Health Ethics

Volume 18, Issue 2, July 2025 http://phe.oxfordjournals.org/content/current [Reviewed earlier]

Public Health Genomics

2025, Vol. 28, No. 1 https://karger.com/phg/issue/28/1 [Reviewed earlier]

Public Health Reports

Volume 140 Issue 4, July/August 2025 https://journals.sagepub.com/toc/phrg/140/4 Research article First published online July 5, 2025

County Influenza Vaccination Rates and Antibiotic Prescribing Rates in US Nursing Homes

Quynh T. Vo, PhD

Qualitative Health Research

Volume 35 Issue 12, October 2025 https://journals.sagepub.com/toc/QHR/current [Reviewed earlier]

Research Ethics

Volume 21 Issue 4, October 2025 http://journals.sagepub.com/toc/reab/current [New issue; No digest content identified]

Reproductive Health

http://www.reproductive-health-journal.com/content [Accessed 11 Oct 2025] [No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

https://www.paho.org/journal/en Latest Articles 10 Oct 2025

<u>Effectiveness of a community strategy for the treatment of tuberculosis in vulnerable contexts in the city of Buenos Aires</u>

Original research | Spanish

Risk Analysis

Volume 45, Issue 9 Pages: 2467-2925 September 2025 https://onlinelibrary.wiley.com/toc/15396924/current [New issue; No digest content identified]

Risk Management and Healthcare Policy

https://www.dovepress.com/risk-management-and-healthcare-policy-archive56 [Accessed 11 Oct 2025] [No new digest content identified]

Royal Society Open Science

October 2025 Volume 12 Issue 10 https://royalsocietypublishing.org/toc/rsos/current [New issue; No digest content identified]

Science

Volume 390| Issue 6769| 9 Oct 2025

https://www.science.org/toc/science/current

Policy Forum

China's emerging regulation toward an open future for AI

BY Yue Zhu, et al. 09 Oct 2025: 132-135

Legislation proposals seek to bring certainty, clarification, harmonization, and simplification

Science and Engineering Ethics

Volume 31, Issue 5 October 2025 https://link.springer.com/journal/11948/volumes-and-issues/31-5 [Reviewed earlier]

Science Translational Medicine

Volume 17| Issue 819| 8 Oct 2025 https://www.science.org/toc/stm/current [New issue; No digest content identified]

Scientific Reports

https://www.nature.com/srep/articles?type=article [Accessed 11 Oct 2025] [No new digest content identified]

Social Science & Medicine

Volume 380 September 2025 https://www.sciencedirect.com/journal/social-science-and-medicine/vol/380/suppl/C [Reviewed earlier]

Systematic Reviews

https://systematicreviewsjournal.biomedcentral.com/articles [Accessed 11 Oct 2025] [No new digest content identified]

Theoretical Medicine and Bioethics

Volume 46, Issue 5 October 2025 https://link.springer.com/journal/11017/volumes-and-issues/46-5 [Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 67 September–October 2025

https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/67/suppl/C Editorial Open access

<u>Immunisation in pregnancy – Weighing the unknown to balance benefits and risks impacting women, offspring, and development</u>

Stephen Toovey, Jessica A. Hellings

Article 102889

Review article Open access

A decade of dengue disease burden in Africa (2013-2023): a systematic review

Gaspary O. Mwanyika, Monika Moir, Abdualmoniem O. Musa, Jenicca Poongavanan, ... Houriiyah Tegally

Article 102897

Tropical Medicine & International Health

Volume 30, Issue 10 Pages: 1025-1143 October 2025 https://onlinelibrary.wiley.com/toc/13653156/current

[New issue; No digest content identified]

Vaccine

Volume 64 3 October 2025 https://www.sciencedirect.com/journal/vaccine/vol/64/suppl/C [Reviewed earlier]

Vaccines

https://www.mdpi.com/journal/vaccines

[Accessed 11 Oct 2025] Open Access Review

<u>Health Technology Assessment of mRNA Vaccines: Clinical, Economic, and Public Health Implications</u>

by Giovanni Genovese, Caterina Elisabetta Rizzo and Cristina Genovese Vaccines 2025, 13(10), 1045; https://doi.org/10.3390/vaccines13101045 - 10 Oct 2025 Abstract

Health Technology Assessment (HTA) is a multidimensional and multidisciplinary approach for analyzing the medical–clinical, social, organizational, economic, ethical, and legal implications of a technology, through the evaluation of multiple dimensions such as efficacy, safety, costs, and social–organizational impact. In the healthcare context, "technology" [...

Open Access Perspective

<u>Advancing Inequality Monitoring in Immunization: Reflecting on 10 Years of WHO</u> Contributions

by Nicole Bergen, Katherine Kirkby, Anne Schlotheuber and Ahmad Reza Hosseinpoor Vaccines 2025, 13(10), 1044; https://doi.org/10.3390/vaccines13101044 - 10 Oct 2025 Abstract

Major immunization programs and initiatives have prioritized the advancement of equity in immunization. Over the past decade, the World Health Organization has made contributions to understanding inequalities in immunization, including global analyses of immunization inequality as well as tools for knowledge dissemination and [...

Open Access Article

<u>Strengthening Primary Health Care Through Implementation Research: Strategies for Reaching Zero-Dose Children in Low- and Middle-Income Countries' Immunization Programs</u>

by Boniface Oyugi, Karin Kallander and A. S. M. Shahabuddin Vaccines 2025, 13(10), 1040; https://doi.org/10.3390/vaccines13101040 - 9 Oct 2025 Abstract

Introduction: Despite global improvements in immunization, major gaps persist. By 2024, an estimated 14.3 million infants, predominantly in low- and middle-income countries (LMICs), remained zero-dose (ZD), never having received even the first DTP vaccine. In 2022, 33 million children missed their measles vaccination [...

Open Access Review

<u>Japanese Encephalitis Vaccine in Low- and Middle-Income Countries (LMICs): A Narrative Review of Efficacy, Effectiveness, Safety, Cost, and Policy</u>

by Eufrasia Ine Pilihanto, Btari Kalisha Nyratri, Muhammad Dafrizal Firdaus and Rano Kurnia Sinuraya Vaccines 2025, 13(10), 1038; https://doi.org/10.3390/vaccines13101038 - 8 Oct 2025

**Abstract*

Japanese Encephalitis (JE) is a mosquito-borne viral infection that causes acute brain inflammation. First identified in Japan in 1871, the disease gained renewed global attention in 2025 after emerging in a non-endemic region, raising significant healthcare concerns. Vaccination remains the most effective strategy [...

Value in Health

October 2025 Volume 28 Issue 10 p1461-1600 https://www.valueinhealthjournal.com/current [New issue; No digest content identified]

World Development

Volume 194 October 2025

https://www.sciencedirect.com/journal/world-development/vol/194/suppl/C

Research article Open access

Violent conflicts and learning outcomes: Evidence from Sub-Saharan Africa

Mhamed Ben Salah, Kritika Saxena

Article 107054

::::::

Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

::::::

Pre-Print Servers

arxiv

https://arxiv.org/

[Accessed 11 Oct 2025]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

arXiv:2510.03566 (cross-list from cs.LG) [pdf, html, other]

<u>CrossLag: Predicting Major Dengue Outbreaks with a Domain Knowledge Informed</u> Transformer

Ashwin Prabu, Nhat Thanh Tran, Guofa Zhou, Jack Xin

Comments: (C) 2025 IEEE. Personal use of this material is permitted. Permission from IEEE must be obtained for all other uses, in any current or future media, including reprinting/republishing this material for advertising or promotional purposes, creating new collective works, for resale or redistribution to servers or lists, or reuse of any copyrighted component of this work in other works

Gates Open Research

https://gatesopenresearch.org/browse/articles

[Accessed 11 Oct 2025] [Filter: All articles]

[No new digest content identified]

medRxiv

https://www.medrxiv.org/content/early/recent

[Accessed 11 Oct 2025] [Filter: All articles]

The projected cost-effectiveness and budget impact of Alternative HPV Vaccines in Senegal: A Modelling Study

Oumaima Laraj, Maryam Diarra, Cheikh Talla, Rokhaya Diop, Ousseynou Badiane, Karell Pelle, Amira Kebir, Cheikh Loucoubar, Slimane Ben Miled

medRxiv 2025.10.08.25337573; doi: https://doi.org/10.1101/2025.10.08.25337573

The Role of Climate Change in the Expansion of Dengue

Rafael de Abreu, Iago Perez Fernandez, Swapnil Mishra, Bernardo Gutierrez, Rhys P.D. Inward, Cathal Mills, Eduardo Lopez Ortiz, Leonardo S. Bastos, Laís Picinini Freitas, Luiz Max Carvalho, Seth Flaxman, Samir Bhatt, Samuel V. Scarpino, Flávio C. Coelho, Robert C. Reiner, Prathyush Sambaturu, Houriiyah Tegally, Simon Cauchemez, Oswaldo Gonçalves Cruz, César V. Munayco, José Alberto Díaz-Quiñonez, Dann Mitchell, Fraser Lott, Francesca Dominici, Oliver G. Pybus, Cláudia Torres Codeço, Marcia C. Castro, Moritz U.G. Kraemer, Sarah Sparrow

medRxiv 2025.10.06.25337235; doi: https://doi.org/10.1101/2025.10.06.25337235

The impacts of United States foreign development assistance reductions on health system building blocks at healthcare facilities in Zambia: a mixed-methods study

Lucy K. Tantum, Darcy M. Anderson, Hikabasa Halwiindi, Michael Herce, Michael T. Mbizvo, Miles A. Kirby, Ryan Cronk

medRxiv 2025.10.06.25337414; doi: https://doi.org/10.1101/2025.10.06.25337414

<u>Approximating vaccine delivery costs to reach zero-dose children: a Bayesian meta-regression analysis</u>

Allison Portnoy, Emma Clarke-Deelder, Taylor A. Holroyd, Daniel R. Hogan, Tewodaj Mengistu medRxiv 2025.10.05.25337360; doi: https://doi.org/10.1101/2025.10.05.25337360

Resilience of health systems in Africa to infectious disease shocks: A systematic review

Denis Okethwangu, Marit Johansen, Sherry Ahirirwe, Mahima Venkateswaran, Roy Mayega, Elizeus Rutebemberwa, Felix Ocom, Victoria Nankabirwa, Charles L. Okot, Evelyne B. Nyachwo, Sandra Nabatanzi, Evelyn Asio, Umaer N. Mohammed, Alex R. Ario, Frode Forland, Suzanne N. Kiwanuka medRxiv 2025.10.03.25337229; doi: https://doi.org/10.1101/2025.10.03.25337229

Routine immunization intensification, vaccination campaigns, and measles transmission in Southern Nigeria

Niket Thakkar, Avuwa Joseph Oteri, Kevin A. McCarthy medRxiv 2025.02.24.25322796; doi: https://doi.org/10.1101/2025.02.24.25322796 Revision

<u>Large Language Models for Detecting CONSORT Guideline Compliance in Published</u> Randomized Clinical Trials: A Cross-Sectional Evaluation Study

Daniel Y Tsybulnik, Justin J Gillette, Thomas F Heston medRxiv 2025.10.03.25337291; doi: https://doi.org/10.1101/2025.10.03.25337291

OSF Pre-prints

https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences
[Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]
[No new digest content identified]

Wellcome Open Research

https://wellcomeopenresearch.org/browse/articles [Accessed 11 Oct 2025] [No new digest content identified]

* * * *

Think Tanks

Brookings [to 11 Oct 2025] http://www.brookings.edu/ Research, Events No new digest content identified.

Center for Global Development [11 Oct 2025]

https://www.cgd ev.org/

All Research

WORKING PAPER

What the Independent Panel for Evidence for Action Against AMR Can Learn from Other Health Panels

Suzanne Edwards and Maple Goh

October 06, 2025

The paper reviews lessons from 17 global health panels to inform the design of the forthcoming Independent Panel for Evidence for Action against Antimicrobial Resistance (IPEA). It finds that IPEA's effectiveness will depend less on structural design and more on strategic positioning—balancing indep...

WORKING PAPER

Evaluating Existing Processes for Uptake of Scientific Evidence on AMR

Elijah Kahn-Woods and Anthony McDonnell

October 06, 2025

Antimicrobial resistance (AMR) represents one of the most pressing global health challenges, yet translating scientific evidence into effective policy has proven slow, uneven, and fragmented across contexts. To inform the design of a proposed Independent Panel for Evidence for Action (IPEA) against

WORKING PAPER

Evaluating Existing Independent and Intergovernmental Panels in Animal Health

Olafur Valsson

October 06, 2025

For the new Independent Panel on Evidence for Action against AMR to be effective, it will need to combine strong mandates, independence, transparent and inclusive membership, and robust evidence frameworks, while balancing agility, accountability, and inclusiveness. Lessons from international expert...

Chatham House [to 11 Oct

20251

https://www.chathamhouse.org/ Selected Analysis, Comment, Events No new digest content identified.

Council on Foreign Relations [11 Oct 2025]

https://www.cfr.org/media/news-releases New Releases [Selected] No new digest content identified.

CSIS [11 Oct 2025] https://www.csis.org/ Reports [Selected] No new digest content identified.

Kaiser Family Foundation/KFF [11 Oct 2025]

https://www.kff.org/search/?post_type=press-release

Newsroom

<u>Poll: After President Trump's Warning, Many People Are Uncertain About Whether Tylenol</u>
<u>Use in Pregnancy Causes Autism; Most Republicans Say It Is Probably or Definitely True</u>
Oct 9, 2025

News Release

Following the Trump administration's warning last month that using acetaminophen – the active ingredient in Tylenol – during pregnancy can increase the risk of autism in children, very few (4%) adults say the claim about a causal relationship is "definitely true," a new KFF Tracking Poll on Health Information and Trust finds.

McKinsey Global Institute [11 Oct 2025]

https://www.mckinsey.com/mgi/overview
Featured Research
No new digest content identified.

ODI [Overseas Development Institute] [to 11 Oct 2025]

https://odi.org/en/publications/ Publications [Selected] No new digest content identified.

Pew Research Center [11 Oct 2025]

https://www.pewresearch.org/ Latest Publications [Selected] No new digest content identified.

Rand [to 11 Oct 2025]

https://www.rand.org/pubs.html Published Research [Selected] Research Oct 10, 2025

<u>Pneumococcal Vaccination Knowledge, Attitudes, and Practices Among Surveyed U.S.</u>
<u>Adults Aged 19-64 Years at Increased Risk for Pneumococcal Disease</u>

To understand factors associated with low vaccination coverage, a web-based survey was conducted among risk-eligible adults examining their knowledge, attitudes, and practices toward pneumococcal vaccinatio *n*.

Urban Institute [to 11 Oct 2025]

https://www.urban.org/research New Research Publications - Selected Research Report

What We Learned about Participatory Research in Prisons

Evaluating the Prison Research and Innovation Initiative
Alice Galley, Evelyn F. McCoy, Sam Tecotzky, Paige Remington, David Pitts
Display Date October 10, 2025

World Economic Forum [to 11 Oct 2025]

https://agenda.weforum.org/press/
Media [Selected]
No new digest content identified.

::::::

Public Consultations/Call for Inputs/Call for Papers

ICH: E20 EWG Adaptive Designs for Clinical Trials

ICH Public consultation dates:

ANMAT, Argentina - Deadline for comments by 8 October 2025 EC, Europe - Deadline for comments by 30 November 2025 Health Canada, Canada - Deadline for comments by 25 September 2025 MHRA, UK - Deadline for comments by 30 November 2025 Swissmedic, Switzerland - Deadline for comments by 30 November 2025 TFDA, Chinese Taipei - Deadline for comments by 13 October 2025 USA, FDA, Deadline 12/01/2025 Docket No. FDA-2025-D-3023 The E20 EWG is working on the development of a new E20 Guideline on "Adaptive Clinical Trials" on the design, conduct, analysis, and interpretation of adaptive clinical trials that provides a transparent and harmonized set of principles for the regulatory review of these studies in a global drug development program. These principles should also provide the flexibility to evaluate / discuss innovative approaches to clinical trial design throughout the development process.

Rapporteur: Dr. Gregory Levin (FDA, United States) Regulatory Chair: Dr. Christian Roes (EC, Europe) Date of Step 2b: 25 June 2025 Status: Step 3

<u>Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket;</u> Request for Comments

A Notice by the Food and Drug Administration on 10/02/2025 **Comments: November 5, 2025** DATES: The meeting will be held on virtually on November 13, 2025, from 10:00 a.m. to 4:00 p.m. Eastern Time (ET).

SUMMARY:

The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pediatric Advisory Committee (PAC). The general function of the Committee is to provide advice and recommendations to FDA on pediatric regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

Comments received on or before November 5, 2025, will be provided to the Committee. Comments received after that date will be taken into consideration by FDA. In the event that the meeting is cancelled, FDA will continue to evaluate any relevant applications or information, and consider any comments submitted to the docket, as appropriate.

The docket number is FDA-2025-N-1246. The docket will close on November 12, 2025.

National Institute of Mental Health, Interagency Autism Coordinating Committee Call for Committee Membership Nominations

A Notice by the National Institutes of Health on 09/24/2025 **Nominations due November 10, 2025.**

SUMMARY:

The Office of the Secretary of the Department of Health and Human Services (HHS) is seeking nominations of individuals to serve as non-federal public members on the Interagency Autism Coordinating Committee (IACC).

The Office of National Autism Coordination (ONAC) of the National Institute of Mental Health, National Institutes of Health is assisting the Department in conducting an open nomination process. Appointments of non-federal public members to the committee shall be made by the Secretary of Health and Human Services.

<u>Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Draft Guidance for Industry; Availability</u>

A Notice by the Food and Drug Administration on 09/25/2025 **Comment period ends 11/24/2025.**

Docket No. FDA-2017-D-6159 :: 21 pages SUMMARY:

This guidance provides sponsors engaged in the development of regenerative medicine therapies for serious or life-threatening diseases or conditions with our recommendations on the expedited development and review of these therapies, including as provided under section 506(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as added by section 3033 of the 21st Century Cures Act (Cures Act). Under section 506(g) of the FD&C Act, a regenerative medicine therapy can be designated as a regenerative advanced therapy if it meets certain criteria. FDA refers to such designation as "regenerative medicine advanced therapy" (RMAT) designation (see section III.C of this document). This guidance describes the expedited programs available to sponsors of regenerative

medicine therapies for serious conditions, including those products designated as RMATs. To that end, the guidance provides information about the provisions in the Cures Act regarding the use of the accelerated approval pathway for regenerative medicine therapies that have been granted designation as an RMAT. Finally, the guidance describes considerations in the clinical development of regenerative medicine therapies and opportunities for sponsors of such products to interact with the Center for Biologics Evaluation and Research (CBER) review staff. As a general matter, this guidance addresses regenerative medicine therapies regulated by CBER as biological products under the FD&C Act, section 351 of the Public Health Service Act (PHS Act) (42 U.S.C. 262), and applicable regulations.

<u>Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small</u>
Populations; Draft Guidance for Industry; Availability

A Notice by the Food and Drug Administration on 09/25/2025 **Comment period ends** (11/24/2025.

<u>Malaria: Developing Drugs for Treatment; Draft Guidance for Industry; Availability</u>

A Notice by the Food and Drug Administration on 09/23/2025. **Comment period ends 12/22/2025.**Docket No. FDA-2025-D-0918

Contents [click to move among sections]

:: Milestones, Perspectives

:: <u>WHO</u>

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (<u>CVEP</u>) / GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the <u>GE2P2 Global Foundation</u> whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the <u>Bill & Melinda Gates Foundation</u> and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.